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SUMMARY 
 
 
 
SUMMARY 
 
Amyotrophic Lateral Sclerosis (ALS) is the most commonly occurring motor neuron disease 
that is fatal and incurable. Motor neurons are markedly vulnerable to excitotoxicity mostly 
from over-stimulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) 
receptors and are principal targets in ALS. Interferon-gamma (IFN-γ), a pro-inflammatory 
cytokine, can independently cause neuronal dysfunction by triggering calcium influx through 
a calcium-permeable complex of IFN-γ receptor 1 (IFN-γR1) subunit and AMPAR subunit 
Glutamate Receptor 1 (GluR1). This receptor complex is formed via a non-canonical neuron-
specific IFN-γ pathway. 
 
 
In this study, we explore the expression of the non-canonical IFN-γ pathway’s key 
 
participants – the upstream targets: IFN-γR1 and GluR1, and the downstream players: Janus 
Kinase 1(JAK1), Signal Transducer and Activator of Transcription (STAT1), and Protein 
Kinase A (PKA) – for the first time in the hSOD1G93A ALS mouse model. Elevated IFN-
γR1 protein expression was observed in motor neurons of both presymptomatic and 
symptomatic hSOD1G93A, while GluR1 protein levels were higher only in the symptomatic 
ALS mice ex vivo. The expression of the downstream participants, namely JAK1 and STAT1, 
were unchanged irrespective of age group and genotype, while one of PKA’s catalytic 
subunits was downregulated at transcript level in hSOD1G93A mice. In in vitro system 
involving primary motor neuron-enriched co-cultures representing the embryonic stage, IFN-
γR1 and GluR1 were similarly expressed in both hSOD1G93A mice and non-transgenic 
control mice. 
 
 
We, also, determined the direct effects of IFN-γ alone or in the presence of an excitotoxic 
 
agent, kainate, on motor neuron survival in vitro. IFN-γ was weakly neurotoxic on the 
 
embryonic motor neurons and did not influence kainate-mediated excitotoxicity. 
 
 
In conclusion, increased IFN-γR1 in motor neurons of adult hSOD1G93A mice can most 
 
likely sensitize the neurons to excitotoxic insults involving GluR1 and/or pathways mediated 
 
by IFN-γ, thus, serving as a potential direct link between neurodegeneration and inflammation 
 
in ALS. 
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ZUSAMMENFASSUNG 
 
 
 
Amyotrophe Lateralsklerose (ALS) ist die am häufigsten auftretende Motoneuronerkrankung, 
 
die sowohl tödlich als auch unheilbar ist. Motoneurone, die Hauptziele in ALS, sind 
 
besonders anfällig für Exzitotoxizität, welche vor allem aus Überstimulation von alpha- 
 
amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) Rezeptoren hervorgeht. Interferon- 
 
gamma (IFN-γ), ein proinflammatorisches Zytokin, kann unabhängig neuronale Dysfunktion 
 
verursachen, in dem es Calciumeinstrom durch einen Calcium-permeablen Komplex der IFN- 
 
γ Rezeptor 1 (IFN-γR1) Untereinheit und der AMPAR Untereinheit Glutamat Rezeptor 1 
 
(GluR1) auslöst. Dieser Rezeptorkomplex wird durch einen unkonventionellen, 
 
neuronspezifischen Signalweg geformt. 
 
 
 
In dieser Studie untersuchen wir die Expression der Schlüsselfaktoren des unkonventionellen 
 
IFN-y Signalweges: die vorgeschalteten Ziele IFN-γ und GluR1 sowie die nachgeschalteten 
 
Faktoren Janus Kinase 1(JAK1), Signal Transducer and Activator of Transcription (STAT1) 
 
und Protein Kinase A (PKA) - zum ersten Mal im hSOD1G93A ALS Mausmodell. Erhöhte 
 
IFN-γR1 Proteinexpression wurde sowohl bei präsymptomatischen als auch symptomatischen 
 
Motoneuronen der hSOD1G93A Mäuse beobachtet, während GluR1 Proteinlevel nur in den 
 
symptomatischen ALS Mäusen ex vivo erhöht waren. Die Expression der nachgeschalteten 
 
Beteiligten JAK1 und STAT1 war unabhängig von Alter und Genotyp unverändert, während 
 
eine katalytische Untereinheit der PKA in hSOD1G93A Mäusen herunter reguliert war. Im in 
 
vitro System, das primäre Motoneuron-angereicherte Kokulturen enthält, die die embryonale 
 
Phase repräsentieren, waren IFN-γR1 und GluR1 sowohl in hSOD1G93A Mäusen als auch 
 
nicht-transgenen Kontrollmäusen gleich exprimiert. Weiterhin ermittelten wir den direkten 
 
Einfluss von IFN-γ allein und in Kombination mit der exzitotoxischen Substanz Kainat auf 
 
Motoneuronüberleben in vitro. IFN-γ wirkte schwach neurotoxisch auf die embryonalen 
 
Motoneurone und übte keinen Einfluss auf die Kainat-vermittelte Exzitotoxizität aus. 
 
 
 
Zusammenfassend ist die erhöhte Expression von IFN-γR1 in Motoneuronen erwachsener 
 
hSOD1G93A Mäuse höchstwahrscheinlich in der Lage, Neurone für GluR1 und/oder IFN-γ 
 
vermittelte Signalwege bedingte Exzitotoxizität zu sensibilisieren. Dies lässt auf eine 
 
potentielle direkte 
 
schließen. 
Verbindung zwischen Neurodegeneration und Entzündung in ALS 
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1. INTRODUCTION 
 
 
 
Neurodegenerative diseases collectively refer to a diverse group of disorders that are defined 
 
by chronic progressive loss of neurons in specific regions of the human central nervous 
 
system, resulting in functional impairments. They are debilitating, incurable, widely 
 
prevalent, and include conditions like Alzheimer’s disease, Parkinson’s disease, and 
 
Amyotrophic Lateral Sclerosis. Most of these diseases are late-onset and affect the elderly. 
 
 
 
The central nervous system (CNS), originally considered to be immune-privileged, is now 
 
recognized to have a unique actively monitoring immune system. In neurodegenerative 
 
conditions, immune activation involves the resident immune cells of the CNS, namely, 
astrocytes and microglia. Initially, the immune responses are acute and typically 
neuroprotective, which later progress to chronic, deleterious kind. These responses trigger 
neuroinflammation that in turn drives neurodegeneration, thus, resulting in a vicious 
degeneration-inflammation cycle. 
 
 
In this thesis, the general objective was to examine a molecular pathway that could be a direct 
 
link between neurodegeneration and neuroinflammation in the neurodegenerative disease 
 
Amyotrophic Lateral Sclerosis (ALS). 
 
 
 
 
 
1.1 General Introduction to ALS 
 
Amyotrophic Lateral Sclerosis or Lou Gehrig’s disease, the most frequent motor neuron 
disease in the world, is a rapidly progressive lethal neurodegenerative disorder destroying 
both the upper and lower motor neurons of the CNS. ALS has an annual incidence of 1-2.6 
cases per 100,000 individuals and an average onset age of 58-60 years (Talbott et al., 2016). 
Patients typically survive 3-4 years post onset and death is mostly due to loss of voluntary 
muscle function, leading to paralysis and respiratory failure. Despite several years of research, 
the disease is yet to find a cure, mostly because of its complex etiology. Thus, studies for 
better understanding of the pathomechanism of this disease are deemed important to identify 
potential therapeutic targets. 
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1.1.1 Diagnosis and treatment of ALS 
 
Clinically, amyotrophic lateral sclerosis patients mostly present with asymmetric limb 
weakness in the 5
th 
or 6
th 
decade of their lives that progress to symmetric peripheral muscle 
paralysis. The limb weakness is observed as deficits in fine motor skills, which is typically 
initially noted in the fingers. This kind of ALS is referred to as limb or spinal-onset ALS 
(Swinnen & Robberecht, 2014) and is, also, the classical form in which the upper extremities 
of the patients are first affected followed by gradual contralateral spread. Signs of motor 
neuron damage in spinal ALS continue to unfold in the contralateral and ipsilateral lower 
extremities as the disease progresses. Head-neck or bulbar-onset ALS, which is characterized 
by symptoms like dysphagia and dysarthria, has fewer cases (20-25%) and are more severe 
with mortality in about 2 years (Figure 1). Irrespective of the onset-type, the clinical features 
typically include muscle atrophy, weakness, spasticity, fasciculations, and hyperreflexia. The 
manifestations are a result of damage to both upper motor neurons (UMNs) present in the 
corticospinal tract and lower motor neurons (LMNs) that innervate the muscles. The disease 
course ultimately culminates with paralysis and death from respiratory failure. 
 
 
 
 
Figure 1. Typical symptoms of 
a patient with ALS. (A) A 64 
year old man suffering from 
ALS with progressive muscle 
weakness. 
 
twitching. 
(B) Bulbar tongue 
 
(C) Hand muscle 
 
atrophy of 60 year old man with 
 
ALS. With permission. Hans 
 
Berger Department of 
 
Neurology, University Hospital, 
 
Jena. 
 
 
 
 
 
Two other rare forms of the disease are peroneal ALS that has a spreading pattern of lower- 
 
upper extremity and respiratory musculature onset ALS causing very early death (Daroff et 
 
al., 2012). Interestingly, the motor neurons that control ocular movement and urethral or 
 
external anal sphincters remain unaffected throughout the entire disease course (Eisen & 
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Weber, 2001). Moreover, ALS has been recently confirmed to be associated with 
 
Frontotemporal Dementia (FTD), with a frequency of 5%-40% (Ferrari et al., 2011). 
 
Frontotemporal Dementia refers to a group of disorders defined by degeneration of basal 
 
ganglia and cerebral cortex neurons, thus, leading to cognitive, language, and behavioural 
 
deficits (Burrell et al., 2016). An ALS/FTD association implies overlapping molecular 
 
pathways critically involved in disease pathogenesis (Weishaupt et al., 2016). These 
 
revelations strongly present the complexity of ALS diagnosis. 
 
 
As per the revised El Escorial Criteria for ALS, the disease diagnosis requires the following: 
 
clinical assessment and presence of both lower and upper motor neuron damage, an evident 
 
advancement in symptoms, and the omission of disease mimics and other causes based on 
 
relevant pathological, neuroimaging, and electrophysiological evidence. Electromyography, 
the only method that can diagnose ALS in its early stages, can reveal active and chronic 
muscle denervation. Currently, there are no blood tests or definitive group of ALS biomarkers 
that could aid diagnosis. The only ALS biomarkers known till date are the phosphorylated 
neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) proteins whose levels 
vary in cerebrospinal fluid and blood serum of ALS patients (Poesen et al., 2017) 
 
 
In terms of disease progression, it is critical to note that the advancement is both curvilinear 
 
and highly variable from patient to patient (Gordon et al., 2010). Existing ALS therapy 
 
comprises of various components: drug treatments, physical therapy, and symptomatic 
 
therapy. Presently, there are no commercially available drugs available to cure ALS. The only 
 
medications available work mostly in slowing the disease progression when administered in 
 
the early stages. Riluzole has been the drug longest in use for ALS until the recent US FDA 
 
approval of another drug, Edaravone. While the former is known to control excitotoxic death, 
 
the latter drug most likely works via its antioxidant properties. 
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1.1.2 ALS pathogenesis 
 
Given the complexity and heterogeneity of ALS, we currently have no unifying explanation 
 
for its pathogenesis. As previously stated, motor neurons are the primary targets with 
 
collateral damage to the glial population to an extent wherein the latter gets involved in 
 
exacerbating the disease condition. 
 
 
 
Motor neuron degeneration in ALS has been attributed to multiple factors that occur in 
 
cohesion or succession: calcium dysregulation, excitotoxicity from excessive glutamatergic 
 
receptor stimulation, neuroinflammation, endoplasmic reticulum stress, mitochondrial 
 
dysfunction, aberrant RNA processing, defective axonal trafficking, excessive protein 
 
aggregation and reactive oxygen species (ROS) generation amongst others (Cozzolino et al., 
 
2012; Tadic et al., 2014; Taylor et al., 2016). 
 
 
 
Based on genetics, ALS can be sporadic or familial depending on the presence of identified 
 
inheritable ALS mutated genes. The disease is mostly sporadic and comprises approximately 
 
90% of the cases. Familial ALS occurrence is due to inheritance of mutations in a mostly 
 
autosomal-dominant manner. Since the identification of first ALS mutation in SOD1 gene for 
 
familial ALS, more than 20 ALS linked genetic loci have been identified. The most frequently 
 
reported ALS inherited mutations are those in C9orf72 (~35% cases), a hexanucleotide repeat 
 
expansion, and SOD1 (~20% cases) (Kirby et al., 2016; Taylor et al., 2016).Interestingly, 
 
several genetic mutations in familial ALS have also been identified in sporadic cases, 
 
especially those in C9orf72 (Kirby et al., 2016) 
 
 
 
Of the various pathogenic factors contributing to ALS, excitotoxicity and neuroinflammation 
 
have long been implicated in disease progression. A pathological process in which neurons 
 
are damaged or killed from excessive stimulation of their receptors for excitatory glutamate, 
 
excitotoxicity is a kind of neurotoxicity implicated in several neurodegenerative conditions 
 
(Dong et al., 2009). Glutamate, the chief excitatory brain neurotransmitter, takes part in this 
kind of neuronal death. Apart from impaired glutamate receptor or relevant ion channel 
functioning, this kind of excitotoxicity can be due to excessive glutamate release and poor 
astrocytic glutamate uptake (Grosskreutz et al., 2010; King et al., 2016). One of the principal 
receptors for glutamate is AMPARs (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptors) that are composed of four subunits: GluR1, GluR2, GluR3, and GluR4. They are 
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typically heterotetrameric wherein two of the four subunits are present as pairs (dimer of 
 
dimers) (Mayer, 2005; Greger et al., 2007). Under physiological conditions, the calcium- 
 
permeable AMPAR stimulation causes calcium influx that activates different signaling 
 
pathways for neuronal functioning. In pathological cases, over-activation of these receptors 
 
causes enormous calcium influx that disturbs intracellular homeostasis and drives the cells 
 
towards apoptosis. 
 
 
 
This type of neuronal death from excessive calcium influx is due to disruption of the 
 
Endoplasmic Reticulum Mitochondria Calcium Cycle (ERMCC) that is involved in regular 
 
calcium buffering dynamics in motor neurons (Grosskreutz et al., 2010; Cozzolino et al., 
 
2012; Tadic et al., 2014). 
 
 
The shuttling of calcium between the ER and mitochondria appears to occur in a cyclic 
 
manner (Grosskreutz et al., 2010; Cozzolino et al., 2012; Tadic et al., 2014), which is referred 
 
to as the ERMCC (Figure 2). Under physiological conditions, AMPAR stimulation triggers an 
 
increase in cytosolic calcium, which in turn is pumped into the ER through the 
 
sarco/endoplasmic reticulum Calcium-ATPase (SERCA). The motor-neuronal ER stores 
 
around 5 times higher magnitude calcium as compared to that present in the cytoplasm 
 
(Stutzmann & Mattson, 2011). This stored calcium could be used to modulate the 
 
excitability, signal amplification, and neurotransmitter release from the neuron, apart from 
 
synchronization of post-translational protein editing with the energy supplied by the ERMCC 
 
(Verkhratsky, 2005; Gunter & Sheu, 2009; Grosskreutz et al., 2010). The pumping in of 
 
calcium induces calcium release from the ER stores through the ryanodine receptors (RyR) 
 
and 1,4,5-triphosphate receptors (IP3Rs) and the process is called Calcium-Induced Calcium 
Release (CICR). This is followed by uptake of calcium by the mitochondria chiefly via the 
Mitochondrial Uniporter (MCU) complex, which is facilitated by the large negative 
membrane potential of the mitochondria. This organelle is known to buffer the lion’s share of 
intracellular calcium in motor neurons. The fact that the blocking of mitochondrial calcium 
buffering quickly depresses neurotransmitter release emphasizes the importance of 
mitochondria in motor-neuronal calcium buffering (Grosskreutz et al., 2010). The 
accumulated calcium is then slowly released back into the cytosol via the mitochondrial 
sodium/calcium exchanger (mNCE) or the transient opening of the mitochondrial 
permeability transition pore (mPTP), only to be later taken up by the ER via the SERCA 
(Tadic et al., 2014). 
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Figure 2. Simplified representation of the ERMCC under physiological conditions (1) 
 
Following α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid receptor (AMPAR) 
stimulation, calcium (Ca
2+
) enters the cytosol. (2) Ryanodine receptor (RyR) on the ER 
membrane senses the increase in cytosolic Ca
2+ 
and releases more Ca
2+ 
from the ER (through 
a process called Ca
2+
-induced Ca
2+     
release). (3) ER Ca
2+     
is released through 1,4,5 
trisphosphate receptor (IP3R), too. Voltage dependent anion channel (VDAC), present in the 
outer mitochondrial membrane, uptakes cytosolic Ca
2+ 
and can directly take up portion of the 
released Ca
2+ 
from the ER as well. Most of the cytosolic Ca
2+ 
uptake by the mitochondria 
takes place through the mitochondrial Ca
2+ 
uniporter (MCU) complex, which is present in the 
inner mitochondrial membrane. (4) Ca
2+     
is released from the mitochondria via the 
mitochondrial sodium Na
+
/Ca
2+ 
exchanger (mNCE). Refilling of the ER Ca
2+ 
stores occurs 
through the sarco/endoplasmic reticulum Ca
2+
-ATPase (SERCA). Additionally, cytosolic 
Ca
2+ 
is cleared by the plasma membrane Ca
2+
-ATPase (PMCA) and the plasma membrane 
Na
+
/Ca
2+
exchanger (pNCE). 
 
 
 
 
In the case of ALS, excessive stimulation of AMPARs results in high levels of cytosolic 
 
calcium that leads to a chronic shift of calcium from ER stores to the mitochondria. While 
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abnormally low levels of ER calcium lead to misfolding of proteins, mitochondrial calcium 
 
overload generates ROS and releases mitochondrial contents like stored ions into the cytosol 
 
via the mPTP and mNCE (Crompton, 1999; Gunter & Sheu, 2009; Grosskreutz et al., 2010; 
 
Barrett et al., 2014; Brini et al., 2014; Tadic et al., 2014). This activates Bcl-2 dependent 
 
apoptotic mechanisms that lead to neuronal death. The glutamate released from damaged 
 
neurons or synaptic clefts extends further damage by acting on surrounding neurons (Choi, 
 
1988). Motor neurons are particularly vulnerable to excitotoxic death owing to high number 
 
of calcium-permeable AMPARs as against low number of intracellular calcium buffering 
 
proteins like parvalbumin and calbindin d-28k and low mitochondrial density per cell volume 
 
(Grosskreutz et al., 2007; Tadic et al., 2014). These attributes of motor neurons are 
 
particularly pronounced in ALS, thus, defining AMPAR excitotoxicity mediated by the 
 
ERMCC as a key pathogenic mechanism in the disease that drives neurodegeneration (Van 
Den Bosch et al., 2006). 
 
 
Concomitant with neurodegeneration is neuroinflammation, a chronic over-activation of the 
 
CNS immune system, which exacerbates the damage in ALS. Initially neuroprotective in 
 
nature, the immune responses soon become toxic, thus, serving as catalysts to the disease 
 
progression. While there is a distinct activation or expansion of glial cells both in vitro and in 
 
vivo, T-lymphocytes have, also, been seen to infiltrate the brains and spinal cords of ALS 
 
cases at different stages of the disease (Philips et al., 2011). Intercellular communication 
 
between the neurons, glia, and lymphocytes is critical in understanding the complexity of the 
 
disease pathogenesis. 
 
 
 
 
 
1.1.3 ALS mouse model with SOD1 mutation: hSOD1G93A 
 
The best and most widely used mouse model for the study of motor neuron death in ALS is 
 
the one that mimics the onset, progression, and severity of the human disease by gross 
 
overexpression (15-20 copies) of human SOD1 transgene having a missense mutation of 
 
guanine to alanine substitution at position 93, namely the hSOD1G93A gene (Gurney et al., 
1994). These mice demonstrate 40-50% motor neuron loss in the lumbar spinal cord by 
disease end stage prior to considerable retraction of nerve terminals from the neuromuscular 
junction. 
 
 
 
7 
INTRODUCTION 
 
 
The SOD1 gene encodes superoxide dismutase-1, a ubiquitously expressed cytosolic enzyme 
 
that scavenges harmful superoxide radicals. Over 150 mutations in the SOD1 have been 
 
associated with ALS that fascinatingly occur throughout the length of the protein rather than 
 
being confined to a specific functional domain (Kirby et al., 2016). Considering that mice 
 
lacking SOD1 do not exhibit motor neuron disease (Reaume et al., 1996), this hSOD1G93A 
 
mouse model suggests that the role of SOD1 gene in ALS is less likely to be a loss of regular 
 
enzymatic function, but rather a gain of toxic function of the protein. 
 
 
 
The hSOD1G93A mouse has been a subject of criticism in ALS research, principally because 
 
of the profound transgene overexpression (15-20 copies) required to recapitulate the disease 
 
and the shortage of experimental findings from the model that have translated therapeutically 
 
to the human condition (Zwiegers & Shaw, 2015). Nevertheless, the hSOD1G93A mouse 
remains one of the most well-characterized and widely-used mouse models for both 
neurodegeneration and inflammation studies in ALS. Moreover, considering that the study 
focuses on the effect of IFN-γ on motor neurons, it was imperative to employ this mouse 
model that recapitulates motor neuron death very well and expresses high levels of pro-
inflammatory cytokines like IFN-γ. 
 
 
 
 
1.2 General Introduction to IFN-γ signaling 
 
Interferon-gamma (IFN-γ) is one of the key cytokines involved in immune and inflammatory 
responses. Its precise role in the central nervous system is still unclear and appears to involve 
a miscellaneous set of responses from different cell types. In the case of neurons, the direct 
effects of this cytokine are yet to be well delineated (Kulkarni et al., 2016). While some 
studies demonstrate its pro-survival role in neurons (Barish et al., 1991; Song et al., 2005; 
O’Donnell et al., 2015), others report detrimental consequences (Kim et al., 2002; Mizuno et 
al., 2008). In the following sections, the cytokine is discussed along with its canonical and 
non-canonical pathways relevant to this study. 
 
 
1.2.1 Interferon gamma (IFN-©) 
 
Interferons (IFNs) were basically described as molecules released by cells to defend viral 
 
infection (Farrar & Schreiber, 1993). Based on their cellular source, biological functions, gene 
 
structure, and the like, this group of signaling proteins is subdivided into 2 classes: Type I and 
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Type II. Type I IFNs are typically generated in response to viral infection. This class of IFNs 
 
is further divided into two: IFN-α family synthesized largely by leukocytes and IFN-β single 
protein largely produced by fibroblasts. IFN-© is Type II IFN that is primarily induced 
by inflammatory and immune stimuli and exclusively produced by T-lymphocytes and 
natural killer cells (Schoenborn & Wilson, 2007). 
 
 
 
IFN-© is a pleiotropic cytokine that promotes both specific and general host defense 
 
mechanisms against infections and tumors (Farrar & Schreiber, 1993). As compared to Type I 
IFNs, IFN-© plays a more exhaustive role in immunomodulation like upregulating 
Major Histocompatibility Class (MHC)-I, inducing MHC-II expression, regulating 
mononuclear phagocytes and humoral immune responses, and synthesis of certain 
proinflammatory or immunomodulatory cytokines (Farrar & Schreiber, 1993). In the lines of 
inflammation, IFN-© is an effector cytokine that regulates macrophage activation 
(phagocytic immune cell) via JAK (Janus kinase)/STAT (Signal Transducer and Activator 
of Transcription) signaling, a pathway that is explained later in this chapter. IFN-© drives 
the macrophages towards the killer “M1” phenotype that leads these cells to express 
high levels of pro-inflammatory cytokines such as TNF-α (Tumor Necrosis Factor-), 
IL(Interleukin)-1, IL-12, and IL-23 and generate excessive reactive nitrogen and oxygen 
species (Martinez & Gordon, 2014). These events promote strong inflammatory activity. It 
would be appropriate to note at this point that microglia, one of the key immune cells 
of CNS and participants in ALS progression, are resident macrophages of the brain and 
spinal cord and follow the mentioned activation pattern. 
 
 
 
In terms of IFN-© expression in the CNS, elevated levels of IFN-© was observed in the 
 
cerebrospinal fluid and serum of ALS patients and the values correlated with disease 
 
progression (Liu et al., 2015). Similarly, this cytokine was shown to be significantly increased 
 
in both the spinal motor neurons and astrocytes of hSOD1G93A mouse at disease onset and 
 
symptomatic stage (Michaelson et al., 2017). Thus, these studies strongly suggest the 
possibility of upregulated IFN-© pathways in the CNS of ALS cases. 
 
 
 
 
 
 
9 
INTRODUCTION 
 
 
1.2.2 IFN-γ receptor complex and canonical IFN-γ signaling 
 
The functional interferon gamma (IFN-©) receptor complex comprises of two 
glycoprotein chains: ligand-binding subunit and signal transducing component. While the 
former is often referred to as IFN-©R1, IFN-© receptor α chain, or CDw119, the latter is 
known as IFN-©R2, IFN-© receptor β chain or accessory factor-1 (AF-1) (Bach et al., 1997). 
 
 
 
IFN-©R1 binds to its ligand, IFN-©, with a high affinity (Ka) of 10
9
-10
10 
M
-1 
with most of 
the extracellular domain (6-227 residues) involved in the activity. This induces rapid 
dimerization of IFN-©R1 subunits resulting in a site that is recognized by the extracellular 
domain of the IFN-©R2 subunits. The dimerization of IFN-©R1 and IFN-©R2 brings 
the two receptor-associated JAKs (Janus Kinases) closer to transactivate and phosphorylate 
the receptor units. This is supported by research that shows the inability of IFN-©R2 to 
transduce signals in response to IFN-© when its JAK2 association site is deleted. 
Crystallographic studies show that the functional IFN-©: IFN-©R complex comprises of the 
IFN-© homodimer bound to two JAK1-associated IFN-©R1 and two JAK2-associated 
IFN-©R2 chains (Bach et al., 1997; Pestka et al., 1997). Transphosphorylation of receptor 
subtypes by the JAKs is followed by phosphorylation of Tyr
440 
in IFN-©R1 by either of the 
kinases. The phosphorylated segments from both the IFN-©R1 chains recruit two 
molecules of STAT1α, which are then phosphorylated by JAK1 and JAK2. This 
results in the formation of functional phosphorylated STAT1 (pSTAT1) homodimer 
that translocates to the nucleus. Subsequently, pSTAT1 binds to DNA sequences called the 
gamma interferon activated site (GAS) with high affinity to start transcription of interferon 
stimulated genes (Shuai et al., 1992; Muller et al., 1993; Darnell et al., 1994; DECKER et 
al., 1997). In parallel, acetylation of pSTAT1 defines the time point for STAT1 inactivation 
wherein complex formation occurs between acetylated STAT1 and the phosphatase T-cell 
protein called tyrosine phosphatase (Krämer et al., 2009). Finally, histone deacetylase 3 
deacetylates STAT1 protein, thus, releasing it to participate in a new cycle of stimulation and 
reactivation (Chen et al., 2012). 
 
 
 
Both the types of IFN-©R subunits belong to cytokine class II receptor superfamily. In 
their dimerized state, the IFN-©R1 chains are 27 Å apart and do not interact with each other 
(Walter et al., 1995). This explains the inability of the IFN-©R1 dimer to induce 
signaling 
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independently despite the presence of both a JAK1 association site and a Stat1 recruitment 
 
site as the physical distance prevents transphosphorylation of the receptor units. 
 
 
 
 
In terms of expression, studies suggest that the levels of the two IFN-©R subunits 
varies greatly across cell types. IFN-©R1 seems to be constitutively expressed on the 
surfaces of nearly all types of cells at moderate levels. In contrast, IFN-©R2 shows 
extremely low constitutive expression with its gene’s transcription under possible tight 
regulation (Pernis et al., 1995; Bach et al., 1997). IFN-©, also, appears to regulate IFN-
©R2 levels in certain cell types (Bach et al., 1997). Surface expression of the fully mature 
protein differs greatly among tissues and, apparently, there is no direct correlation between 
extent of IFN-©R1 expression and degree of IFN-© induced response (Farrar & 
Schreiber, 1993). The IFN-©R1 gene is encoded on chromosome 6q for humans and 
chromosome 10 for mouse, while the IFN-©R2 is encoded on chromosome 21q for humans 
and 16 for mouse (Hibino et al., 1991; Cook et al., 1994; Soh et al., 1994). Overall speaking, 
although IFN-©R complex is ubiquitously present in cells, the role of the receptor is complex 
and not, yet, very well understood: for example, the reason behind its inability to support all 
known actions of IFN-© is still under investigation. 
 
 
 
1.2.3 Neuron-specific non-canonical IFN-γ pathway regulating calcium 
Apart from the classical IFN-γ signaling involving JAK1/STAT1, there are several other non-
canonical IFN-γ pathways that may or may not be STAT1 dependent. The functioning of 
these pathways is cell and context-dependent. Existence of these pathways presents the 
complexity of IFN-γ signaling and varied roles of the cytokine both in immune and 
inflammatory responses. 
 
 
 
In neurons, IFN-γ is known to induce neurotoxicity through a non-canonical pathway 
 
involving IFN-γR1 and GluR1 subunits from IFN-γR and AMPAR respectively that causes 
 
increased calcium influx. Several studies report the ability of IFN-γ to directly induce calcium 
 
transients possibly via calcium channels or by opening intracellular calcium stores in different 
 
cell types (Hansen ’ et al., 1994; Kung et al., 1995; Martino et al., 1996; AAS et al., 1998; 
 
Franciosi et al., 2002). In neurons, however, the cytokine triggers calcium influx by inducing 
 
a calcium-permeable receptor complex formation between IFN-γR1 and GluR1 as was 
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demonstrated in mouse cortical neurons in vitro (Mizuno et al., 2008). The cytokine binds to 
 
IFN-γR1, which results in activation of downstream JAK1/STAT1. Activated STAT1 
 
mediates elevation in cAMP levels via adenylyl cyclase activity leading to activation of PKA 
 
(Protein Kinase A). Finally, PKA mediates the IFN-γR1:GluR1 complex formation by 
 
phosphorylating GluR1 at serine 845 position (Figure 3). Increased calcium influx elevates 
 
intracellular nitric oxide levels that damage the mitochondria, thus, resulting in drop in ATP 
 
levels and subsequent neuronal damage. 
 
The ability of IFN-γR1 to couple with neuron-specific calcium permeable AMPAR presents a 
 
potential neurotoxic mechanism that can play a role in both neurodegenerative and 
 
inflammatory diseases. In this study, we examine the pathway in the context of ALS using the 
 
mouse model hSOD1G93A. 
 
 
 
 
 
Figure 3. IFN-γR1:GluR1 pathway. Mizuno, 
 
T., et al. (2008). "Interferon-gamma directly 
 
induces neurotoxicity through a neuron 
 
specific, calcium-permeable complex of IFN- 
 
gamma receptor and AMPA GluR1 receptor." 
 
FASEB J 22(6): 1797-1806. IFN-γ binding to 
 
IFN-γR activates Jak1/STAT1 signaling that 
 
elevates cAMP levels from increased adenylyl 
 
cyclase (AC) activity and activates PKA. 
 
Phosphorylation of GluR1 by PKA at serine- 
 
845 induces calcium-permeable receptor 
 
complex formation with IFN-γR1 and 
increased calcium influx leads to enhanced 
nitric oxide production. This results in 
neuronal     dysfunction     via     inhibition     of 
mitochondrial respiratory chain. 
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2. AIMS OF STUDY 
 
 
 
This study’s hypothesis is principally based on two well-established facts: First, motor 
 
neurons are particularly susceptible to excitotoxic death owing to high number of AMPARs 
 
and low levels of calcium buffering proteins. Second, IFN-γ independently induces calcium 
 
influx in neurons by initiating a neuron-specific calcium permeable complex formation 
 
involving IFN-γR1 and AMPAR subunit GluR1. Considering that IFN-γ holds the potential to 
 
enhance neuronal death in a fashion akin to AMPARs, examining this cytokine and its 
 
receptor can serve as a possible direct link between neurodegeneration and neuroinflammation 
 
in ALS. 
 
 
 
 
The study examines this calcium-transients inducing non-canonical IFN-γ pathway in motor 
 
neurons from both non-transgenic and hSOD1G93A mice. Reckoning the potential of 
 
AMPAR and IFN-γR stimulation in triggering neurotoxicity, the hypothesis is that the IFN-γ 
 
inducing motor neuron damage would be observed in both mouse systems, with a special 
 
element of aggravation in hSOD1G93A mice. 
 
 
 
 
On these lines, the aims of this study include the following: 
 
 examine the expression levels of the primary targets, IFN-γR1 and GluR1, in vitro 
 
 demonstrate the effect of IFN-γ on motor neuron survival in vitro 
 
 study the cytokine’s influence in regulating calcium levels in motor neurons in vitro 
 
Apart from examining primary mouse motor neurons in vitro that is representative of 
 
embryonic stage, this study gathered insights on the pathway’s participants in the adult mice, 
 
ex vivo. For this, the following were examined in the motor neurons of hSOD1G93A mice, 
 
both before and after disease onset, alongwith those of age-matched non-transgenic adult 
mice: 
 
 expression of upstream targets, IFN-γR1 & GluR1 
 
 levels of downstream targets JAK1, STAT1, and Protein Kinase A 
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For expression studies, both mRNA and protein levels were measured. The functional studies 
 
to determine the effects of IFN-γ in vitro comprised of cell survival study and single-cell 
 
calcium measurements. 
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3. MATERIALS AND METHODS 
 
 
 
3.1 Animals 
 
All animal care, husbandry, and experimentation were performed according to the guidelines 
set by the Directives of the Protection of Animals Act and agreed upon by the animal welfare 
authorities of Thuringia, Germany (accreditation number: 02-046/14). Mice were monitored 
regularly for motor impairment and euthanized upon onset of major paralysis to alleviate 
suffering. Transgenic hemizygous hSOD1G93A male mice expressing high copy number of 
the mutated allele of human SOD1 gene (Gurney et al., 1994) B6.Cg-
Tg(SOD1*G93A)1Gur/J (stock number 004435) were acquired from Jackson Laboratory (Bar 
Harbor, ME, USA) and bred with non-transgenic C57BL/6J females to produce transgenic 
(hSOD1G93A) and non-transgenic (control) mice. The genotypes were confirmed by 
Polymerase Chain Reaction (PCR) on tail biopsies. All animals were maintained in controlled 
laboratory conditions comprising of 10/14 h light-dark cycle and ad libitum access to standard 
diet and tap water. The hemizygotes exhibit adult-onset neurodegeneration of spinal motor 
neurons leading to progressive motor deficits & paralysis, similar to ALS patients. The 
hSOD1G93A mice in our laboratory on C57BL/6J (non-transgenic) background live up to 
157.1 ± 9.3 days (https://www.jax.org/strain/004435). Their weight gain is slower than their 
non-transgenic littermates due to the denervation of muscles and subsequent atrophy (Figure 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Body mass of hSOD1G93A mice decreases over time when compared to non-
transgenic mice. hSOD1G93A mice (n = 181) exhibit weight loss due to muscle atrophy 
when compared to healthy non-transgenic mice (n = 12). Data for only male mice are shown. 
Mann Whitney U test. ***p ≤ 0.001. 
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3.2 Mouse primary motor neuron-enriched co-cultures 
 
Spinal cords from 13 day old hSOD1G93A and non-transgenic embryos were extracted for 
cell isolation. Genotype verification was as suggested by the Jackson Laboratory. Motor 
neuron-astrocyte primary co-cultures were prepared as previously described (Van Den Bosch 
et al., 2000; Van Damme et al., 2003) (Figure 5). The mice embryonic ventral spinal cords 
were dissected and the subsequently extracted motor neurons were seeded on previously 
prepared glial feeder monolayers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic for primary motor neuron enriched co-culture preparation from 
mice. Hemizygous hSOD1G3A male is mated with C57BL/6J female. Embryos are 
collected from the pregnant C57BL/6J mouse at E13 followed by their genotyping and 
spinal cords isolation. Dissection of ventral horns from embryonic spinal cords is followed 
by cell dissociation from the tissue and density-gradient centrifugation. Finally, the 
astrocyte-enriched pellet is seeded to generate feeder monolayers while the spinal neuron 
fraction is seeded on previously generated feeder astrocyte monolayers. Images of the mice 
are adapted from Jackson laboratories (https://www.jax.org/). 
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3.2.1 Genotyping mice embryos 
 
For DNA isolation, 0.2 cm of the tail biopsy from each mouse was treated with 75 μL of 
 
alkaline lysis reagent containing 37.5 μL of 25 mM NaOH solution (Riedel-de Haën, 
 
Germany) in deionized water and 37.5 μL of 0.2 mM ethylenediaminetetraacetic acid (EDTA, 
 
Sigma-Aldrich). After incubating at 95 °C for 30 minutes, the specimens were cooled on ice 
 
for 5 minutes. Thereafter, 75 μL of neutralizing agent containing 40 mM tris(hydroxymethyl)- 
 
aminomethane hydrochloride (TrisHCl, Roth, Germany) in distilled water was added. 1 μL 
 
from each treated sample was subjected to polymerase chain reaction (PCR). For this, 10 μL 
 
of MasterMix (5 Prime), 1 μL of each primer (Table 10) (Biomers.net, Germany) and 1 μL of 
 
DNA (described above) were added to 10 μL of deionised water in a 0.5 mLeppendorf tube 
 
(Eppendorf, Germany). By employing a T3 Thermocycler (Biometra, Germany), PCR was 
 
accomplished following the program steps from Table 12. The amplified products were run 
 
on 1.5% agarose gel (Sigma-Aldrich, Germany). 
 
 
 
 
 
3.2.2 Cell culture plates preparation for seeding motor neurons 
 
Prior to seeding motor neurons, autoclaved 12 mm glass coverslips (Marienfeld GmbH) were 
placed in 24 well NunclonTM Surface plates (Nunc A/S, Denmark) and coated with 150 μL 
of poly-D-lysine hydrobromide solution (PDL, Sigma-Aldrich). Post 1 hr incubation at 37°C, 
PDL was removed and the coverslips were washed twice with 500 μL of distilled water 
followed by addition of 500 μL astrocyte media (Table 1). The plates were kept in the 
incubator at 37 °C and 5 % CO2 until seeding. 
 
 
 
3.2.3 Generating motor-neuron-enriched co-cultures 
 
Female non-transgenic mice were mated with male hSOD1G93A mice. On day 13 of the 
pregnancy, the females were sacrificed by cervical dislocation. Each deceased animal was 
drenched with 70% ethanol (Nordhäuser Ethanol, Germany) to restrict fur contamination. The 
abdominal pelt was removed and uterus was cut at the mesentery. The uterus and amnions 
were operated upon to extract the embryos. A piece of the tail from each embryo was excised 
for genotyping. Subsequently, the ventral spinal cords from hSOD1G93A and non-transgenic 
embryos were dissected and pooled separately into two 15 mLfalcon tubes containing cold 
modified HBSS. 
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To reach the spinal cord, each embryo was pinned with a needle followed by removal of the 
 
skin overlying the spinal cord. Dorsal sections of the spinal cord and lumbar regions were 
 
excised to extract the ventral horns. Tissue preparation and genotyping of embryos were done 
 
by Svetlana Tausch. 
 
The pooled spinal cord sections were washed thrice with 5 mLice-cold modified HBSS and 
 
digested with 0.1% trypsin (Gibco, UK, prepared in modified HBSS) for 15 min in a 37 °C 
 
waterbath. Subsequently, the tissues were placed on ice and allowed to settle. For trituration, 
 
trypsin was discarded and 4 mLof motor neuron medium (Table 1) along with 80 µl ice-cold 
 
DNase (AppliChem, Germany) was added. The suspension was agitated for 1-2 minutes to 
 
separate the digested tissues. Addition of the medium, also, stopped traces of the trypsin’s 
 
activity. After the tissues settled, they were slowly triturated using fire-polished glass pipettes 
 
to obtain even cell suspension. For isolation of motor-neuron enriched fraction and glial cells, 
 
the homogenized solution was subjected to density gradient centrifugation with 6.2% 
 
OptiPrep density gradient solution (OptiPrep, Axis-shield Poc AS, Norway) dissolved in L-15 
 
media (Sigma-Aldrich, Germany). Astrocyte feeder monolayers were generated by seeding 
 
the glial cells on previously prepared 12-mm PDL-coated coverslips (50,000 cells/coverslip). 
 
Glial medium (Table 1), for the first week media change, contained 10% fetal calf serum 
 
(FCS, PAN Biotech, Germany). This supports viability and attachment of the astrocytes to 
 
the PDL-coated coverslips. Subsequently, FCS was replaced by 10% horse serum (Gibco, 
 
UK). The glial cells multiplied till they reached 60-70% confluency after which the cell 
 
division was arrested by applying 5 µM arabinofuranosyl cytidine (Calbiochem, Germany) for 
 
24 hr. Spinal motor-neuron enriched fractions were seeded on the glial feeder monolayers 
 
(15,000 cells/coverslip for viability assay or immunocytochemistry and 30,000 cells/coverslip 
 
for calcium imaging). From the time of seeding the motor neurons, media change was with 
 
500 µl of motor neuron medium (Table 1) per well. On day 13 in vitro, the motor neuron co- 
 
cultures were used for the experiments. 
 
 
 
 
3.3 Mice cervical sections 
 
3.3.1 Spinal cord isolation 
 
For ex vivo studies, both presymptomatic and symptomatic hSOD1G93A animals were used 
along with age-matched controls (Tables 4 & 5). Mice were first placed in Plexiglas 
cylindrical chambers and anesthetized until cardiac arrest using isoflurane (Isoflurane-CP, 
CP-Pharma, Germany). The gas was injected into the sealed chambers using Isoflurane Vapor 
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19.3 (Drägerwerk AG, Germany). Subsequently, the mice required for cervical section 
 
preparation and immunohistochemistry were perfused with PBS (Phosphate Buffered Saline) 
 
for 2 minutes followed by a perfusion with 4% ice-cold PFA (paraformaldehyde) to fix the 
 
organ tissues. Post perfusion, the mice were decapitated close to their heads. After opening 
 
the spinal canals, the cervical regions were severed from the spinal cords and the overhanging 
 
nerve roots were trimmed. The spinal cord regions were incubated in ice-cold 4% PFA 
 
overnight. Following this, the specimens were immersed in 10% sucrose solution maintained 
 
at 4°C and incubated overnight. Finally, they were incubated at 4°C in 30% sucrose till they 
 
sunk in the solution. The segments were then frozen in Tissue-Tek® (Sakura, Netherlands) at 
 
-20°C. On the other hand, for mRNA expression studies, the mice employed were decapitated 
 
after successful anesthesia without perfusion. The entire spinal columns were extracted and 
 
stored at -80°C in Tissue Tek. 
 
 
 
 
3.3.2 Spinal cord section preparation 
 
The cervical regions of hSOD1G93A and non-transgenic mice were taken and the CM3050S 
cryostat (Leica, Germany) maintained at -19°C was employed for slicing. Each spinal cord 
region was immobilized on the instrument’s carrier plate using Tissue-Tek® and sliced to 
generate 16 μm thick sections. As and when they were sliced, the tissue sections were directly 
transferred on to SuperFrost Plus® (Thermo-Fisher Scientific™, USA) slides that were pre-
warmed to 37°C. Around 10 slices were mounted per slide. Afterwards, the slides were stored 
at -20°C. 
 
 
 
3.4 Protein expression studies 
 
3.4.1 Immunofluorescence of motor-neuron-enriched co-cultures 
 
To distinguish neuronal cell types (motor neurons from non-motor neurons), determine the 
distribution and quantify expression of IFN-γR1and GluR1 at the embryonic stage, and 
ascertain dendritic beads formation upon IFN-γ stimulation, immunocytochemistry was 
performed on primary motor-neuron-enriched co-cultures. The cells from both the genotypes 
were fixed with 4% PFA for 20 minutes at room temperature. Following double wash with 1X 
PBS, cells were incubated for 2 hr with 10% normal goat serum (Gibco, UK) that was 
dissolved in modified PBS (1X PBS + 3% bovine albumin serum (BSA, SERVA) + 0.3% 
Triton X-100 (Sigma-Aldrich, USA)) at room temperature to prevent unspecific secondary 
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antibody binding. Primary antibodies were diluted in 2% normal goat serum containing 
 
modified PBS. Cells were incubated in primary antibody solution according to the protocols 
 
detailed in Table 6. The employed primary antibodies consisted of mouse anti-SMI32 
 
(801701, BioLegend, USA, 1:1000) for motor neuron marker, rabbit anti-βIII-tubulin (T2200, 
 
Sigma Aldrich, Germany, 1:250) for general cytoskeleton marker, rabbit anti-MAP-2 
 
(ab32454, Abcam, UK, 1:200) rabbit polyclonal anti-IFN-γR1 (sc-702, Santa Cruz 
 
Biotechnology Inc., CA, USA, 1:200), and rabbit anti-GluR1 (ab31232, Abcam, UK, 1:200). 
 
Post antibody incubation, the cells were washed twice with 1X PBS and incubated with the 
 
appropriate secondary antibody dissolved in modified PBS containing 10% NGS (Table 6). 
 
Thereafter, a double wash with PBS was followed by staining of all the nuclei with 
 
4', 6-diamidino-2-phenylindole (DAPI, Sigma, USA) for 5 minutes. The last step involved 
 
washing out of DAPI with 1X PBS and mounting of the coverslips with Fluoromount-G 
(SouthernBiotech, UK). 
 
 
 
 
3.4.2 Immunohistochemistry of spinal cord sections 
 
Slides containing the spinal cord sections stored in -20°C were transferred to glass cuvettes 
and left to dry in a cabinet maintained at 37°C for 30 minutes. They were then incubated with 
1% SDS (Sodiumdodecyl sulfate) at room temperature for 5 minutes for antigen retrieval. 
Subsequently, the spinal cord sections were rinsed twice with 1X PBS for 5 and 10 minutes. 2 
hr incubation with 10% normal goat serum was carried out for blocking at room temperature. 
Tissue slices were stained using primary antibodies of rabbit anti-IFN-γR1(sc-702, Santa Cruz 
Biotechnology Inc., CA, USA, 1:200), rabbit anti-GluR1 (ab31232, Abcam, UK, 1:200), 
monoclonal rabbit anti-phospho-Stat1(Tyr701) antibody (Cell Signaling Technology, 
Danvers, MA, USA, 1:250), or rabbit anti-JAK1 (H-106, Santa Cruz, 1:250) along with 
mouse anti-SMI32 (1:1000) that were dissolved in 2% NGS. The antibody solution was added 
onto the slides and covered with Parafilm® (Bemis, USA). The slides were carefully 
transferred to a wet chamber and kept for 48 hours at 4°C. Subsequently, the slides were 
washed in 1X PBS thrice for 15 minutes each time. Secondary antibodies Alexa 488 goat anti-
rabbit and Alexa 594 goat anti-mouse diluted in 10% NGS were added. Incubation was for 1 
hr at room temperature, which was followed by 1X PBS wash twice. 
Thereafter, the slices were stained with DAPI for nuclei identification by immersing the slides 
in the solution for 5 minutes. Finally, the sections were thoroughly rinsed with 1X PBS and 
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mounted with Fluoromount-G® (SouthernBiotech, USA). The specimens were stored at 4°C 
 
in the dark until analyses were performed. 
 
 
 
 
3.4.3 Quantification of immunofluorescence signal 
 
For the motor-neuron co-cultures, immunofluorescence signals representing protein 
expression levels of IFN-©R1and GluR1 were quantified in non-transgenic and 
hSOD1G93A motor neurons. At least 5 neurons from each coverslip out of a set of 3 
coverslips per motor neuron culture preparation were imaged. This was repeated for at least 3 
different cell culture preparations (1 n = 1 motor neuron). For ex vivo expression studies, at 
least 15 cells from the anterior horns of 3 spinal cord sections (cervical) of one animal were 
imaged (1 n = 1 neuron). Immunofluorescence signals of IFN-γR1, GluR1, JAK1, and 
phosphorylated STAT1 were quantified. High resolution volumetric images of the stained 
motor neurons were generated by acquiring sequential optical sections (z-stacks) in high 
magnification (63X oil immersion) through confocal laser scanning microscopy (LSM 
710, Zeiss, Germany) having constant settings (PMT voltage, scan speed, pinhole etc.). 
For image processing, ZEN 2012 software (Zeiss, Germany) was employed. Integrated 
fluorescence density and mean fluorescence were measured with the “z-project” plugin of 
the Fiji Is Just ImageJ software 2014 (Fiji, open source software based on ImageJ 
modified by BioVoxxel, Mutterstadt, Germany). To measure protein expression, the 
corrected total cell fluorescence (CTCF) was computed using the formula: CTCF = 
Integrated density of selection – (Area of the selection X Mean fluorescence of 
background readings) (Gavet & Pines, 2010). CTCF data from single motor neurons 
belonging to the same genotype were pooled (1 cell = 1 n). 
 
 
3.5 mRNA expression studies 
 
3.5.1 Sample preparation from motor neuron co-cultures and spinal cords 
qPCR was performed in collaboration with Madlen Gunther to determine mRNA levels of 
targets of interest (IFN-γR1, GluR1, JAK1, Stat1, PKA isoforms). For mRNA measurements 
in embryonic system, cells from three coverslips of each motor neuron-enriched co-culture 
preparation were pooled as one sample (1 preparation = 1 n) after adding 100 µl QIAzol lysis 
reagent (Qiagen, USA) to each well. 
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For ex-vivo expression studies, the spinal columns were transferred to liquid nitrogen vessels 
 
and 1µl QIAzol Lysis Reagent was added to each specimen. The tissues were homogenized in 
 
Ultrathorax (Miccra, Germany) for 10-20 seconds. 
 
 
 
 
3.5.2 RNA isolation 
 
Total RNA from primary cells and spinal cord tissue were extracted by employing the 
phenol/chloroform extraction method. The samples, after lysis, were allowed to rest for 5 
minutes at room temperature, after which they were dissolved in 200 μL of chloroform 
(Sigma-Aldrich, USA). After vigorously shaking by hand for 15 s and incubating for 3 
minutes at room temperature, the samples were centrifuged at 12000xg for 15 minutes at 4°C. 
Subsequently, the liquid phase of the solution from the surface was extracted for each sample 
and collected in a new tube. The RNA in the collected aqueous phase was then precipitated 
with 1.1-fold volume of isopropranol (Sigma-Aldrich, USA) and 0.16-fold volume of 2M 
sodium acetate (Sigma-Aldrich, USA) at pH 4. After dissolving, the RNA containing solution 
was maintained at -20°C overnight. Subsequently, the suspension was again centrifuged at 
12000xg for 15 minutes at 4°C. The supernatant was discarded and the pellet containing RNA 
was washed with 1 mLof 75% ethanol, dissolved using a vortex shaker, and centrifuged at 
7500xg for 10 minutes at 4°C. Subsequently, the pellet was again washed with the same 
amount of ethanol after removing the supernatant. The pellet was spun down and the rest of 
the liquid was then pipetted out. Finally, after air-drying for 5-10 minutes, the pellet was 
dissolved in 40 μL of DEPC-H2O (Gibco, UK) by pipetting up and down for 5 minutes at 
65°C. The RNA was stored at -80°C after determining its concentration using NanoDrop 2000 
(Peqlab Biotechnologies,Germany). 
 
 
 
3.5.3 cDNA synthesis 
 
To synthesize cDNA, total RNA (500ng) was transcribed using the Revert Aid First strand 
cDNA synthesis kit (ThermoFisher Scientific, USA). Briefly, 0.5μL random hexamer primer, 
0.6μL oligo (dT) 18 primer, and 5μL RNA were mixed in a 0.2μL reaction tube at 4°C. 
Subsequently, the tube was subjected to 65°C for 5 minutes followed by incubation for at 
least 2 minutes at 4°C. Based on the number of samples, the master mix was made with 2μL 
of 5x reaction buffer, 1μL of 10mM deoxynucleoside triphosphates (dNTPs), 0.5μL of 
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RNAse inhibitor and 0.5μL of reverse transcriptase. The master mix was then added to the 
 
pre-incubated RNA sample followed by pipetting up and down to mix the solutions. This 
 
final mixture was then subjected to a thermal cycling program (25°C for 5 minutes, 42°C for 
 
60 minutes, 70°C for 5 minutes). The generated cDNA was diluted with distilled water at a 
 
1:10 ratio to obtain a final concentration of 5ng/μL. 
 
 
 
 
3.5.4 qPCR reaction 
 
qPCR was done with SYBR Green III Master Mix (Agilent Technologies, USA) as formerly 
described (Jaenisch et al., 2016). 10μL of 10X SYBR Green III Master Mix and 5μL of 2μM 
Primermix (Biomers.net, Germany) were mixed in a reaction tube. The mRNAs of target 
interests were normalized to a housekeeping gene -- hydroxymethylbilane synthase (hmbs) or 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primers used for qPCR are listed in 
Table 9. 
 
 
To 5μL of previously obtained cDNA, 15μL of the SYBR Green reaction mixture was added 
 
followed by running it in Corbett Rotor Gene 6000 PCR cycler (Corbett Life Science Pty. 
 
Ltd., Australia) using the following thermal cycling program: polymerase activation at 95°C 
 
for 3 minutes, 40 amplification cycles (95°C for 10 s, 60°C for 15 s) followed by melting 
 
curve measurement. The relative mRNA expression of target proteins for each hSOD1G93A 
 
sample was calculated to the mean value from non-transgenic sample by applying Pfaffl 
 
equation (Pfaffl, 2001). Apart from cycle threshold (Ct), the qPCR efficiency (E) and melting 
 
temperature of the product were supplied by the commercially available software of the PCR 
 
cycler. While the Ct value suggests the number of cycles required for the product’s 
 
fluorescence signal to cross the set threshold, availability of the melting temperature ensures 
 
that the product is specifically amplified. The Pfaffl equation that was employed for 
 
calculations is given below: 
R = {(Etarget sequence)
Ct target control – Ct target sample
}/{(Ereference sequence)
Ct reference control – Ct reference sample
} 
Subsequently, the geometric mean of R for all the animal groups was determined. 
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3.6 Functional tests for IFN-γ 
 
3.6.1 Staining and visualizing dendritic beads in vitro 
 
At the outset, for functional studies, it was appropriate to verify if IFN-γ exerts visible effects 
that could be visualized as dendritic beads in the motor neurons from the cell culture system 
employed in this study. To determine this, day 13 in vitro primary motor neuron-enriched 
cultures of both hSOD1G93A and non-transgenic genotypes were treated with 100 ng/mLof 
recombinant IFN-γ for 12 hr. Subsequently, the co-cultures were stained for MAP-2 and 
SMI32 and observed under 20X magnification of a fluorescence microscope (LSM 710, 
Zeiss, Germany). 
 
 
 
 
3.6.2 Cell survival study on primary motor-neuron-enriched co-cultures 
 
To determine effect of IFN-γ on motor neuron survival, we tested the cytokine’s independent 
 
impact as well as its role in AMPAR-mediated excitotoxicity. In this study, the potent 
 
AMPAR receptor agonist kainate was used to induce excitotoxicity. Thus, the treatment 
 
strategy involved application of recombinant IFN-γ alone or in combination with kainate. On 
day 13 in vitro, motor neuron enriched cultures were treated for 12 hr and 24 hr at 37
o
C in a 
humidified CO2 incubator with (Table 13): 100 µM kainate (Abcam, UK) and/or 100 
ng/mLIFN-γ (R & D Systems, USA). The cells were fixed with 4 % PFA and blocked with 
10% normal goat serum in 1% BSA. Following this, they were stained with the neuronal 
general cytoskeleton marker βIII-tubulin and motor neuron marker SMI32. The numbers of 
βIII-tubulin-positive neurons representing all neurons and βIII-tubulin+SMI32-positive 
neurons representing the motor neuron kind were counted in characteristic areas per coverslip 
by an investigator blinded to the experimental conditions. All the coverslips were examined 
under a fluorescence microscope (Axioplan 2 imaging, Zeiss, Germany) at 20X magnification 
in atleast 3 independent repeats. The numbers were compared to native (untreated) controls. 
 
 
 
 
3.6.3 Single cell cytosolic calcium measurements 
Cytosolic calcium (Ca
2+
) measurement was by means of Fura-2 single cell imaging. Motor 
neuron enriched co-cultures were loaded with 5-10 μM of the membrane permeable ester 
form of the high-affinity ratiometric fluorescent dye Fura-2AM (Sigma Aldrich, Germany) for 
25 minutes at 37°C. After dye de-esterification at room temperature, motor neuron-enriched 
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culture containing coverslip was mounted onto the stage of an upright microscope (Nikon 
 
Microscope Eclipse FN1, Tokyo, Japan) that was constantly perfused with a standard 
 
extracellular solution containing (in mM): 3.2 CaCl2, 129.1 NaCl, 11.6 HEPES, 5.9 KCl, 1.2 
MgCl2, and 11.5 glucose and pH adjusted to 7.4 with NaOH (Table 14). Cell visualization 
was by using a water immersion objective (NIR Apo, 40X/0.80 W, DIC N2, ∞/0, WD 3.5) 
(Nikon, Tokyo, Japan) and exciting Fura-2 at 350 and 380 nm wavelengths (Polychrome V, 
TillPhotonics, Gräfelfing, Germany). Emission light transmitted through the dichroic mirror 
(DCLP410) and emission filter (LP440, both obtained from TillPhotonics) was collected by a 
cooled CCD camera (iXONEM+, ANDOR™, UK) as described previously (Grosskreutz et al., 
2007). Ratiometric fluorescent images were captured using the Till Vision Imaging System 
(TillPhotonics, Gräfelfing, Germany). To determine the direct effect of IFN-γ on intracellular 
Ca
2+ 
at single-cell level, varying doses (100 ng/mL, 200 ng/mL, and 500 ng/mL) of IFN-γ 
were directly applied for durations ranging from 2 s at 30 s intervals to 2 hr without intervals. 
Also, cells were pre-incubated with 100 ng/mLof IFN-γ for 30 or 60 minutes and subjected to 
kainate for 2 s at 30 s intervals. The calcium measurements were done both in the presence 
and absence of other channel blockers, namely 200 μM verapamil (Sigma-Aldrich, Germany) 
and 0.5μM tetrodotoxin (Biotrend, Germany). While verapamil blocks the voltage-gated 
calcium channels, tetrodotoxin selectively blocks voltage-gated sodium channels. In the case 
of using channel blockers, the extracellular solution used to superfuse the cells, also, 
contained these two substances during the entire measurement course. 
 
 
 
 
3.7 Statistics 
 
The statistical analyses were performed using GraphPad Prism Version 5.00 for Windows. 
Data are given as mean ± SEM except for that of survival study in which the data are 
provided as mean ± SD. Scatter plots, box plots (min, max, quartile) and bar charts have been 
used for data representations. All the analyzed data were tested for normality and equal 
variances. For non-parametric data, Mann-Whitney test was employed to compare two 
groups. ANOVA with Bonferroni’s correction as post-hoc test was used for multiple 
comparisons. The threshold for statistical significance was considered at p < 0.05. 
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3.8 Buffers, media, and other consumables 
 
 
3.8.1 Media preparation and materials for motor-neuron co-cultures 
 
Media Components Concentration 
 
 
Astrocyte medium 
DMEM / Ham’s F-12 Medium 
 
FCS or horse serum 
 
Penicillin-Streptomycin 
Base 
 
10% 
 
1% 
 
 
 
 
 
 
Motor neuron medium 
Neurobasal Medium 
 
B27 Neuromix (50x) 
 
BDNF 
 
Horse serum 
 
L-Glutamine 
 
N2 Supplement (100x) 
 
Penicillin-Streptomycin 
Base 
 
2% 
 
2 ng/mL 
 
2% 
 
1 mM 
 
0,2% 
 
1% 
 
 
Modified HBSS 
HBSS 
 
HEPES 
 
Penicillin-Streptomycin 
Base 
 
1 M 
 
1% 
 
 
 
PBS 
KCl 
 
KH2PO4 
NaCl 
NaHPO4 
2.7 mM 
 
1.8 mM 
 
137 mM 
 
10 mM 
 
 
Table 1. Media and buffers used for cell culture and immunocytochemistry. HBSS: 
 
Hank’s Balanced Salt Solution, KCl: Potassium Chloride, KH2PO4: Potassium Dihydrogen 
Phosphate, NaCl: Sodium Chloride, PBS: Phosphate-Buffered Saline. FCS: Fetal Calf Serum, 
DMEM: Dulbecco's Modified Eagle Medium; BDNF: Brain-derived neurotrophic factor, 
HEPES: (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
MATERIALS AND METHODS 
 
 
 
 
 
Substances Manufacturer 
1-β-Arabinofuranosylcytosine (AraC) Calbiochem, Germany 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Roth, Germany 
Absolute ethanol for analysis Merck, Germany 
Acetic acid Roth, Germany 
B27 NeuroMix (50x) Gibco, UK 
Bovine serum albumin (BSA) SERVA, Germany 
DNase I AppliChem, USA 
Dulbecco’s modified Eagle’s medium (DMEM) / Ham’s F-12 
Medium (1:1) without L-glutamine 
Gibco, UK 
Fetal calf serum (FCS) PAN Biotech, Germany 
Ham’s F-12 Medium (1:1) without L-Glutamine Gibco, UK 
Hank’s balanced salt solution (HBSS) Gibco, UK 
HCl Sigma, USA 
Horse serum Gibco, UK 
KCl Merck, Germany 
L-15 Medium Leibovitz without L-glutamine Sigma, Germany 
L-Glutamine (200mM 100x) Gibco, UK 
NaHPO4 Roth, Germany 
N2 supplement (100x) Gibco, UK 
NaCl Roth, Germany 
Neurobasal medium without L-Glutamine Gibco, UK 
Normal goat serum (NGS) Gibco, UK 
OptiPrepTM AXIS-SHIELD, Norway 
Penicillin-Streptomycin Gibco, UK 
Poly-D-lysine hydrobromide Sigma Aldrich, USA 
Recombinant human brain-derived neurotrophic factor (BDNF) PeproTech, USA 
Sodiumdodecylsulfate (SDS) SERVA, Germany 
Sodium hydroxide (NaOH) Sigma, Germany 
Tris (hydroxymethyl) aminoethane hydrochloride (TrisHCl) Roth, Germany 
Trypsin Gibco, UK 
Water for injection Fresenius Kabi, GER 
 
 
Table 2. Ingredients for cell culture preparation. 
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Consumable Properties Manufacturer 
24-well plates  Greiner Bio-One, Germany 
Biosphere filter tips Different sizes Sarstedt, Germany 
Coverslips Diameter = 12mm Marienfeld GmbH & Co KG, Germany 
Eppendorf tubes 0.5ml, 1.5ml, 2ml, 5ml Eppendorf, Germany 
Falcon tubes 15ml; 50ml Greiner Bio-One, Germany 
Nunclon Surface plates  Nunc A/S, Denmark 
Pasteur pipettes 230mm Assistent, Germany 
Transfer pipettes  Sarstedt, Germany 
 
 
Table 3. Laboratory consumables for cell culture preparation. 
 
 
 
3.8.2 Animals for ex-vivo studies 
 
 
 
 hSOD1G93A C57BL/6J 
Presymptomatic group 3 (9 - 9.1 weeks old) 3 (8.1 weeks old) 
Symptomatic group 3 (19.6 - 20.6 weeks old) 3 (21.3 weeks old) 
 
 
Table 4. Number of animals used per group for protein expression studies (CTCF 
 
evaluation) 
 
 
 
 
 
 hSOD1G93A C57BL/6J 
Presymptomatic group 6 (9.2 – 10.2 weeks old) 3 (9.8 weeks old) 
Symptomatic group 7 (19 - 21.3 weeks old) 5 (17.7-21 weeks old) 
 
 
Table 5. Number of animals used per group for relative mRNA expression studies 
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3.8.3 Ingredients for immunofluorescence staining protocols 
 
Target 
 
of 
 
interest 
Primary antibody Dilution, 
 
temperature, 
 
& 
 
incubation 
 
period 
Secondary antibody Dilution, 
 
temperature, 
 
& 
 
incubation 
 
period 
βIII 
 
tubulin 
Rabbit anti-β- 
 
tubulin III, Sigma 
 
Aldrich 
1:250, RT, 
 
1 hr 
Alexa 488 goat anti- 
 
rabbit, Invitrogen; USA 
1:250, RT, 
 
1 hr 
GluR1 Rabbit anti-GluR1, 
 
Abcam 
1:100, 4
o
C, 
 
overnight 
Alexa 488 goat anti- 
 
rabbit, Invitrogen; USA 
1:250, RT, 
 
1hr 
IFN-γR1 Rabbit anti-IFN-
©R1 , Santa 
Cruz 
1:200, 4
o
C, 
 
overnight 
Alexa 488 goat anti- 
 
rabbit, Invitrogen; USA 
1:250, RT, 
 
1hr 
JAK1 Rabbit anti-JAK1, 
 
Santa Cruz 
1:250, 4
o
C, 
 
overnight 
Alexa 488 goat anti- 
 
rabbit, Invitrogen; USA 
1:250, RT, 
 
1hr 
MAP-2 Rabbit anti-MAP2, 
 
Abcam 
1:200, RT, 
 
1 hr 
Alexa 488 goat anti- 
 
rabbit, Invitrogen; USA 
1:250, RT, 
 
1hr 
pSTAT1 Rabbit anti- 
 
phosphoStat1(Tyr7 
 
01), Cell Signaling 
 
Technology 
1:250, 4
o
C, 
 
overnight 
Alexa 488 goat anti- 
 
rabbit, Invitrogen; USA 
1:250, RT, 
 
1hr 
SMI32 Mouse anti-SMI32, 
 
BioLegend, USA, 
1:1000, 4
o
C, 
 
overnight 
Alexa 594 goat anti- 
 
mouse, Invitrogen; 
 
USA 
1:250, RT, 
 
1hr 
 
 
Table 6. Primary and secondary antibody list alongwith protocols for staining. GluR1: 
 
Glutamate Receptor 1, IFN-γR1: Interferon-Gamma Receptor 1, JAK1: Janus Kinase 1, 
 
MAP-2: Microtubule-Associated Protein 2, pSTAT1: Phosphorylated STAT1(Signal 
Transducer and Activator of Transcription 1), SMI32: Motor neuron neurofilament marker 
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Solution/Buffer Constitution 
Modified Phosphate 
 
Buffer Saline (PBS) 
3% Bovine Serum Albumin (BSA) and 0.3% Triton-X-100 in 
 
1X PBS 
Sodiumdodecyl Sulfate 
 
(SDS) solution 
1% SDS in 1X PBS 
Blocking and secondary 
 
antibody solution 
10% Normal Goat Serum in modified PBS 
Primary antibody 
 
solution 
2% Normal Goat Serum in modified PBS 
 
 
Table 7. Buffers and solutions used for immunostaining 
 
 
 
3.8.4 Materials for PCR and qPCR 
 
 
 
Commercial kit/substance Constituents Manufacturer, 
 
Location 
Revert aid first strand cDNA 
 
synthesis kit 
Oligo (dT) primer 
 
Random hexamer primer 
 
5x Reaction buffer 
 
Deoxynucleotriphosphates (dNTPs) 
 
RNAse inhibitor (20U/μl) 
 
Reverse transcriptase (200U/μl) 
Thermo Fisher 
 
Scientific, USA 
10X SYBR Green III Master 
 
Mix 
 Agilent Technologies, 
 
USA 
 
 
Table 8. Commercial kit and other relevant materials for qPCR. 
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Gene Primer sequences Product Size 
Gapdh Fwd: CAACAGCAACTCCCACTCTTC 
Rev: GGTCCAGGGTTTCTTACTCCTT 
164 bp 
hmbs Fwd: GAAATCATTGCTATGTCCACCA 
Rev: GCGTTTTCTAGCTCCTTGGTAA 
98 bp 
GRIA1 Fwd: CAAATCCCGTAGCGAGTCGA 
Rev: TCTGCCATTCTCTCCACTGC 
144 bp 
IFN-©R1 Fwd: GGTGGTTGCTCCTCTTACCG 
Rev: ACCACAGAGAGCAAGGACTTAG 
120 bp 
JAK1 Fwd: CTGAGGTATTGGGTGGCCAG 
Rev: CTTATGTTGTCCGTGCGCAG 
154 bp 
Prkaca Fwd: TTTGCCAAGCGTGTGAAAGG 
Rev: GTAACCAGCAGCCATCTCGT 
147 bp 
Prkacb Fwd: TGCAGCCCAGATTGTGCTAA 
Rev: ATGTCCATGTCCTGCCCTTG 
155 bp 
Stat1 Fwd: CTGCTGTGCCTCTGGAATGA 
Rev: TGAATGTGATGGCCCCTTCC 
139 bp 
 
 
Table 9. Primers for qPCR. GRIA1: Glutamate Receptor 1, IFN-©R1: Interferon-Gamma 
 
Receptor 1, JAK1: Janus Kinase 1, Prkaca: Protein Kinase A catalytic subunit A, Prkacb: 
 
Protein Kinase A catalytic subunit B, Stat1: Signal Transducer and Activator of Transcription 
 
1 
 
 
 
 
 
Primer name Primer sequence 
Internal control (oIMR7338) Fwd: CTAGGCCACAGAATTGAAAGATCT 
Internal control (oIMR7339) Rev: GTAGGTGGAAATTCTAGCATCATCC 
Transgenic SOD1 (oIMR0113) Fwd: CATCAGCCCTAATCCATCTGA 
Transgenic SOD1 (oIMR0114) Rev: CGCGACTAACAATCAAAGTGA 
 
 
Table 10. Primers for genotyping mouse embryos. 
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Material Constituents Company 
PCR Master Mix Taq DNA Polymerase (62.5U/mL), 125mM KCl, 
0.25% Igepal®-CA360, 500M of each dNTP, 
75mM Tris-HCl pH 8.3, 3.75mM Mg(OAc)2, and 
stabilizers 
5Prime, Germany 
Primer Mix  Biomers.net, Germany 
 
 
Table 11. Materials for PCR. KCl: Potassium Chloride, dNTP: deoxynucleotriphosphates, 
 
Mg(OAc)2: Magnesium acetate 
 
 
 
 
 
Cycle Step Temperature Time period No. of cycles 
Initial Denaturation 95°C 3 minutes 1 
Denaturation 
 
Annealing 
 
Elongation 
95°C 
 
60°C 
 
72°C 
30 seconds 
 
30 seconds 
 
45 seconds 
35 times in sequence 
Final denaturation 72°C 2 minutes 1 
 
 
Table 12. PCR thermal cycling program for genotyping of hSOD1G93A mice 
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3.8.5 Chemicals used for cell survival study and calcium measurements 
 
Chemical Stock Concentration Solvent Manufacturer 
Kainate 10mM Purified water Abcam, UK 
IFN-γ 100µg/ml 1X PBS with 0.2% BSA R&D Systems, USA 
Tetrodotoxin 1mM Purified water Biotrend, Germany 
Verapamil 20mM DMSO:Purified water 
 
(1 : 4) 
Sigma Aldrich, Germany 
Fura-2AM 2mM DMSO Sigma Aldrich, USA 
 
 
Table 13. Substances used for cell survival study and calcium imaging. 
 
Constituent Concentration Company 
CaCl2 3.2 mM Roth, Germany 
HEPES 11.6 mM Roth, Germany 
KCl 5.9 mM Roth, Germany 
MgCl2 1.2 mM Roth, Germany 
NaCl 129.1 mM Merck, Germany 
 
 
Table 14. Composition of extracellular solution used for calcium imaging. CaCl2: 
Calcium Chloride, HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, KCl: 
potassium chloride, MgCl2: magnesium chloride, NaCl: sodium chloride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
MATERIALS AND METHODS 
 
 
3.8.6 Hardware list 
 
Instrument Company, Location 
Centrifuge 5415 R Eppendorf, Germany 
Corbett Rotor Gene 6000 PCR cycler Corbett Life Science Pty. Ltd., Australia 
Cryostat CM3050S Leica, Germany 
D-6450 Type T6120 Drying cabinet Heraeus, Germany 
Isoflurane Vapor 19.3 Drägerwerk, Germany 
Laser scanning microscope 710 (LSM 710) Carl Zeiss, Germany 
Miccra D1 Miccra, Germany 
Nanodrop 2000 Peqlab Technologies, Germany 
T3 Thermocycler Biometra, Germany 
 
 
Table 15. List of instruments used for the study 
 
 
 
 
 
3.8.7 Software list 
 
Software Name Organization 
BLAST NCBI 
FIJI/Image J BioVoxxel, Germany 
GraphPad Prism GraphPad Software Inc., USA 
Mendeley Elsevier 
Microsoft Office Word 2003 & 2010 Microsoft, USA 
Till Vision Till Photonics, Germany 
Zen 2012 Carl Zeiss, Germany 
 
 
Table 16. List of software employed for the study 
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4. RESULTS 
 
 
 
4.1 In vitro expression and function studies 
 
 
4.1.1 Treating primary motor-neuron co-cultures with recombinant IFN-γ 
induced dendritic bead formation 
To determine if IFN-γ independently exerts any conspicuous effects, the primary motor 
neuron enriched co-cultures were treated with 100 ng/mLof recombinant IFN-γ for 12 hr. 
Upon staining for MAP-2 and observing under 20X magnification, dendritic beads were 
clearly visible in both hSOD1G93A and non-transgenic cultures. Irrespective of the genotype, 
IFN-γ induced dendritic beads in the motor neurons (Figure 6). To investigate the extent of 
damage, percentage of dendritic bead bearing motor neurons out of total number of motor 
neurons were determined in 3 independent repeats. Again, all the motor neurons exhibited 
beading in both the genotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. IFN-γ independently induces damage in spinal motor neurons that are 
visualized as dendritic beads under 20X magnification. Scale bar = 20 μm (A) Untreated 
non-transgenic spinal motor neurons showing smooth dendrites after MAP-2 staining. IFN-γ 
independently induces dendritic beads in both (B) non-transgenic and (C) hSOD1G93A motor 
neurons. 
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4.1.2 Direct application of IFN-γ maintains AMPAR mediated 
excitotoxicity in motor neurons 
With visible structural changes observation in motor neurons upon IFN-γ application, the next 
objective was to determine this cytokine’s effects on motor neuron survival. 
 
 
As kainate, a potent AMPAR agonist, and IFN-γ are capable of triggering calcium influx 
 
unaided, they were applied independently or in combination to examine excitotoxicity in 
 
motor neurons. E13 motor-neuron-enriched co-cultures were treated for 12 hr or 24 hr with 
 
100μM kainate and 100ng/mLIFN-γ in combination as well as alone. Untreated culture wells 
 
served as controls. Thus, there were 4 groups for each round of experiment for each genotype: 
 
Untreated, kainate treated, IFN-γ treated, and kainate + IFN-γ treated. Post incubation, the 
surviving neurons were stained for β-III tubulin and SMI32. They were then counted under 
20X magnification by an investigator blinded to the treatment conditions (Figure 7). 
 
 
Figure 7. Representative image for 
 
neuron counting in survival study. 
Scale bar = 50 μm. For each coverslip, 
total number of neurons identified by β-
III tubulin staining were counted under 
a fluorescence microscope in the green 
channel followed by a switch to the red 
channel to count the number of motor 
neurons alone that were identified by 
SMI32 staining. 
 
 
As seen with cortical neurons in vitro in a previous study (Mizuno et al., 2008), regardless of 
 
the incubation time, IFN-γ independently did not exert lethal effect on non-transgenic or 
 
hSOD1G93A motor neurons when compared to the untreated group (Figure 8). However, 
 
stimulation with both kainate and IFN-γ also did not enhance excitotoxic effect of kainate in 
 
non-transgenic (n = 9) and hSOD1G93A (n = 12) motor neurons after 12 hr incubation 
 
(Figure 8A). Similar results were seen post 24 hr incubation in hSOD1G93A (n = 9) and non- 
 
transgenic (n = 9) motor neurons (Figure 8B). This observation contrasted with the one in the 
 
cortical neuron study wherein IFN-γ was shown to promote excitotoxic death in cortical 
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neurons (Mizuno et al., 2008). Thus, AMPAR mediated excitotoxicity in spinal motor 
 
neurons in vitro appears to be unaltered by the presence of IFN-γ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Kainate-induced AMPAR excitotoxicity unaffected by IFN-γ. (A) Both non- 
 
transgenic (n = 9) and hSOD1G93A (n = 12) motor neuron co-cultures were treated with 
 
combination of IFN-γ and kainate or either of the agents for 12 hr. Kainate treatment induces 
 
strong neuronal death and IFN-γ does not appear to add excitotoxic insult (B) A 24 hr 
 
treatment yields similar decrease in motor neuron survival post kainate treatment, independent 
 
of IFN-γ in both non-transgenic (n = 9) and hSOD1G93A (n = 9) motor neurons. Each 
 
column indicates mean ± SD. One-way ANOVA with Bonferroni correction. 
 
 
 
4.1.3 Irrespective of the genotype, IFN-γ triggers weak cytosolic calcium 
 
signals in single motor neurons in vitro 
 
To examine the effects of IFN-γ alone on the cytosolic calcium levels of hSOD1G93A motor 
neurons as against non-transgenic motor neurons at single cell level, calcium measurements 
were performed. The process began with attempting to elicit calcium responses by applying 
low doses (100ng/mL, 200ng/mL) of IFN-γ in the presence of other channel blockers, 
verapamil and tetrodotoxin (TTX), for short time: 2s at 100s intervals directly to the primary 
motor neuron cultures. This stimulation protocol is established in our group for AMPAR 
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stimulation with kainate. The stimulation hardly yielded significant responses. The neurons 
 
that did respond gave out weak signals at random time points for both the genotypes. 
 
 
Reckoning that the dose was probably low for a sufficient response, the concentration was 
 
increased by at least 5 times and 500 ng/mLof IFN-γ was applied in the presence of other 
 
channel blockers, verapamil and TTX. Regardless of hSOD1G93A presence, both short-term 
 
(2 s exposure at 100 s intervals) and long-term (1 min to 1 hr) exposure mostly yielded 
 
no/inconsistent weak responses. The direct application protocols of high and low doses were, 
 
also, tested in the absence of the channel blockers and the results were similar as the previous 
 
ones in both non-transgenic and hSOD1G93A motor neuron cultures. Next, the primary motor 
 
neuron co-cultures were pre-incubated with IFN-γ for 30 or 60 minutes to sensitize the IFN- 
 
γR1, which was followed by application of our established kainate stimulation protocol. The 
objective was to stimulate AMPARs after possible sensitizing of the IFN-©R with its 
cytokine. The responses were typical of that from sole kainate application, irrespective of the 
genotype. Moreover, cycles of direct IFN-γ application for 2s followed by 100s washout 
and a 2s kainate pulse also resulted in responses comparable to sole kainate application. Due 
to lack of consistent, measurable calcium responses from IFN-γ application (both direct and 
indirect), statistical analyses weren’t performed. To determine if there was any difference in 
the number of neurons between non-transgenic and hSOD1G93A that responded to all 
the tested protocols, we compared the percentages of responding neurons of both the 
genotypes. The percentages were very similar (Figure 9C). Moreover, we pooled calcium 
measurements from one of the tested protocols of direct IFN-γ application with 3 
independent repeats to get collective representative images of inconsistent weak responses 
from non-transgenic (n =16) (Figure 9A) and hSOD1G93A (n = 13) (Figure 9B) neurons. 
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Figure 9. Evaluation of cytosolic calcium levels after direct application of IFN-γ. 
Representative recording of cytosolic calcium measurement in (A) hSOD1G93A (n = 13) 
motor neurons and (B) non-transgenic (n = 16) motor neurons. IFN-γ was directly applied 
for 2 s at 100 s intervals in the presence of channel blockers verapamil and tetradotoxin. 
Similarly, measurements were carried out under different experimental conditions. All of 
them yielded weak, inconsistent responses. (C) Counting the percentage of neurons that 
responded from all the experimental conditions yielded similar numbers in both non-
transgenic and hSOD1G93A genotypes. 
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A. 100 ng/mLIFN-γ in the 
 
presence of Verapamil 
 
(VP) and Tetrodotoxin 
 
(TTX) for 2 seconds at 
 
100 second interval 
 3 different 
 
preparations 
B. 200 ng/mLIFN-γ in the 
 
presence of Verapamil 
 
(VP) and Tetrodotoxin 
(TTX) for 2 seconds at 
100 second interval 
 2 different 
 
preparations 
C. 100 ng/mLIFN-γ in the 
 
absence of Verapamil 
 
(VP) and Tetrodotoxin 
 
(TTX) for 2 seconds at 
 
100 second interval 
 3 different 
 
preparations 
D. 500 ng/mLIFN-γ in the 
 
presence of Verapamil 
(VP) and Tetrodotoxin 
(TTX) for 2 seconds at 
100 second interval 
 2 different 
 
preparations 
E. 200 ng/mLIFN-γ in the 
 
absence of Verapamil 
 
(VP) and Tetrodotoxin 
 
(TTX) for 1.5-2 hours 
 3 different 
 
preparations 
 
RESULTS 
 
 
Table 17. Calcium traces from IFN-γ stimulation by direct application. 
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4.1.4 IFN-γR1 expression is unchanged in the presence of hSOD1G93A 
gene in spinal motor neurons in vitro 
To determine if hSOD1G93A gene influences IFN-γ’s direct target, IFN-γR1, the distribution 
and basal expression of this subunit was examined in primary motor neurons in vitro. 13 day 
old primary co-cultures from both hSOD1G93A and non-transgenic mice were subjected to 
immunocytochemistry for IFN-γR1 along with the motor neuron marker, SMI32. 
 
 
Upon visualizing under high magnification (63X oil immersion objective), IFN-γR1 was 
 
observed to be uniformly distributed across the motor neuron somas (Figure 10A) in both 
 
non-transgenic and hSOD1G93A motor neurons. Interestingly, signals were also observed in 
 
the nuclei of motor neurons from both the genotypes. Upon quantifying the 
 
immunofluorescence signals in the form of CTCF and comparing the values between non- 
 
transgenic (n = 60) and hSOD1G93A (n = 62), similar levels of IFN-γR1 (Figure 10B) were 
 
determined in the motor neurons. This was supported by quantitative PCR results that 
 
measured the relative mRNA levels for the receptor subunit in non-transgenic (n = 13) and 
 
hSOD1G93A (n = 11) (Figure 10C) motor neuron co-cultures. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. IFN-γR1 expression in embryonic motor neurons from primary co-
culture. (A) IFN-γR1 observed in green channel is uniformly distributed across the 
somas of both hSOD1G93A (G93A) and non-transgenic (nontg) motor neurons. Scale 
bar = 10μm. (B) Protein expression measured as CTCF by immunofluorescence. CTCF 
of IFN-γR1 in G93A motor neurons (n = 62) was similar to that in nontg motor neurons 
(n = 60). (C) The relative expression of IFN-γR1 gene is normalised to GAPDH for 
nontg (n = 13) and G93A (n = 11) samples. The mRNA levels were similar in both the 
groups. Each column indicates mean ± SEM. Mann-Whitney test. 
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4.1.5 GluR1 levels similar in hSOD1G93A and non-transgenic motor 
neurons in vitro 
Followed by determining IFN-©R1 levels, the expression of GluR1, the other principal 
target of the IFN-γ non-canonical pathway, in hSOD1G93A and non-transgenic motor 
neurons was analyzed in vitro. Immunostaining the primary motor neuron cultures for 
GluR1 along with SMI32 in both the genotypes revealed uniform distribution of the receptor 
subunit across the motor neuron somas (Figure 11A). 
Protein levels were similar in hSOD1G93A (n = 45) and non-transgenic (n = 45) motor 
neurons as was observed from comparing the CTCF values (Figure 11B) in the motor 
neurons. The relative mRNA levels for GluR1 in non-transgenic (n = 13) and hSOD1G93A (n 
= 11) (Figure 11C) motor neuron co-cultures, also, supported the immunofluorescence 
observation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. GluR1 expression in embryonic motor neurons studied in primary co-
cultures. (A) Representative images of GluR1 that is uniformly distributed across the somas 
of both non-transgenic (nontg) and transgenic (G93A) motor neurons. Scale bar = 10 μm. (B) 
Protein expression measured as CTCF after immunofluorescence showed similar levels in 
G93A motor neurons (n = 45) and nontg motor neurons (n = 45). (C) The relative expression 
of GluR1 gene was normalised to GAPDH for nontg (n = 13) and G93A (n = 11) samples. 
The mRNA levels were similar in both the groups. Each column indicates mean ± SEM. 
Mann-Whitney test. 
 
 
 
Taken together, the in vitro studies show that despite the presence of hSOD1G93A gene, 
 
direct application of IFN-γ neither significantly alters cytosolic calcium levels nor enhances 
 
kainate-mediated excitotoxicity. Moreover, expression of the principal receptor units, IFN-
©R1and GluR1, was unchanged between the genotypes. 
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4.2 Ex vivo studies 
 
4.2.1 Higher IFN-©R1 protein levels in motor neurons from cervical 
 
sections of both presymptomatic and symptomatic hSOD1G93A mice 
Inflammation is mostly a late-stage event both in terms of lifespan and ALS disease. It is 
observed typically after disease onset. Thus, the pathway’s principal targets were examined in 
adult mice ex vivo. Presymptomatic and symptomatic hSOD1G93A mice alongwith age-
matched controls were used for the study. Cervical sections obtained from presymptomatic 
(Figure 12A) and symptomatic (Figure 12B) mice were immunostained and quantified for 
IFN-©R1 in the motor neurons. Two-way ANOVA following Bonferroni’s post hoc correction 
for IFN-γR1 CTCF showed a signiﬁcant effect of genotype (F1,88 = 57.53, p-value < 0.0001), 
unlike that of age (F1,88 = 2.36, p-value = 0.1285) or genotype x age interaction (F1,88 = 1.51, 
p-value = 0.2225) (Figure 12C) on IFN-γR1 expression. 
 
 
 
4.2.2 Relative mRNA levels for IFN-©R1 similar in hSOD1G93A and non- 
 
transgenic mice 
 
Relative mRNA levels of IFN-γR1 were, also, measured. For this purpose, whole spinal cords 
from symptomatic and presymptomatic mice were taken. The mRNA levels were normalized 
to the stable housekeeping gene hmbs. qPCR showed similar relative mRNA levels in both 
non-transgenic (9 weeks: n = 3, 17 weeks: n = 5) and hSOD1G93A (9 weeks: n = 6, 17 weeks: 
n = 8) mice (Figure 12D) in both the age groups. 
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Figure 12. IFN-γR1 expression ex vivo. Images represent single-plane confocal scans of 
 
motor neurons in anterior horn of the cervical spinal cord section. Green channel shows IFN- 
 
γR1 protein expression in motor neurons of (A) presymptomatic and (B) symptomatic mice in 
 
both the genotypes. Scale bar = 10 μm. (C) IFN-γR1 protein expression was measured as 
 
CTCF (AU). Significantly increased IFN-γR1 CTCF was determined in motor neurons of 
 
both symptomatic (n = 45 from 3 mice) and presymptomatic (n = 45 from 3 mice) G93A mice 
 
when compared to age matched nontg controls (n = 45 from 3 mice for each age group). ***p 
 
≤ 0.001. Two-way ANOVA with Bonferroni's correction. (D) Relative IFN-γR1 mRNA was 
 
similar in whole spinal cords of G93A (9 weeks: n=6, 21 weeks: n=8) mice when compared to 
 
age matched nontg controls (9 weeks: n=3, 21 weeks: n=5) irrespective of the age group. 
 
Mann-Whitney test between every two groups. Data presented as scatter plots in one graph as 
 
mean ± SEM. 
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4.2.3 Elevated GluR1 in cervical sections of symptomatic hSOD1G93A 
mice motor neurons 
Expression of the pathway’s other principal primary target, GluR1, was studied. Cervical 
sections sliced from spinal cords of presymptomatic (Figure 13A) and symptomatic (Figure 
13B) mice were immunostained and quantified for GluR1 in the motor neurons. On 
comparing CTCF values using two-way ANOVA, a signiﬁcant effect of genotype (F1,88 = 
20.36, p-value = 0.002) and genotype x age interaction (F1,88 = 13.96, p-value = 0.0104), 
unlike that of age (F1,88 = 1.11, p-value = 0.2874) was observed for GluR1 expression (Figure 
13C). 
 
 
 
4.2.4 Similar relative mRNA levels of GluR1 in hSOD1G93A and non-
transgenic mice 
Whole spinal cords from both hSOD1G93A and non-transgenic mice for both age groups 
were collected for relative mRNA measurement of GluR1. The housekeeping gene hmbs 
expression was employed for normalization. Similar levels of mRNA were observed in both 
the genotypes irrespective of age group: non-transgenic (9 weeks: n = 3, 17 weeks: n = 5) and 
hSOD1G93A mice (9 weeks: n = 6, 17 weeks: n = 8) (Figure 13D) 
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Figure 13. GluR1 expression ex vivo. Images represent single-plane confocal scans of motor 
 
neurons in anterior horn of the cervical spinal cord section. Green channel shows GluR1 
 
protein expression in motor neurons of (A) presymptomatic and (B) symptomatic mice in both 
 
the genotypes. Scale bar = 10 μm. (C) GluR1 protein expression was measured as CTCF 
 
(AU). Significantly increased GluR1 CTCF was determined in motor neurons of symptomatic 
 
G93A mice (n = 45 from 3 mice) as against presymptomatic (n = 45 from 3 mice) group and 
 
age-matched nontg control (n = 45 from 3 mice). **p = 0.002, *p = 0.0104. Two-way 
 
ANOVA with Bonferroni's correction. (D) Relative GluR1 mRNA is similar in whole spinal 
 
cords of G93A (9 weeks: n=6, 21 weeks: n=8) mice when compared to age matched nontg 
 
controls (9 weeks: n=3, 21 weeks: n=5) irrespective of the age group. Mann-Whitney test 
between every two groups. Data presented as scatter plots in one graph as mean ± SEM. 
 
 
 
 
 
 
 
 
 
46 
RESULTS 
 
 
4.2.5 Similar JAK1 levels in adult hSOD1G93A and non-transgenic mice 
motor neurons. 
With primary participants of the IFN-γ mediated neuron-specific pathway detected at elevated 
levels, especially in the symptomatic hSOD1G93A mice, the next step was to investigate the 
expression of the pathway’s key downstream players, namely JAK1, phosphorylated STAT1, 
and Protein Kinase A (PKA). JAK1 protein expression was examined in spinal motor neurons 
of presymptomatic as well as symptomatic hSOD1G93A mice and their age-matched non-
transgenic controls. Cervical sections were stained for SMI32, the selective motor neuron 
marker, and the target protein JAK1. The signaling protein was distributed uniformly across 
the cell somas (Figure 14A, 14B). Comparing the CTCF values from non-transgenic and 
hSOD1G93A by two-way ANOVA revealed no significant effects of genotype (F1,88 = 3, p-
value = 0.0876), age (F1,88 = 3.39, p-value = 0.07) and genotype x age interaction (F1,88 = 1.61, 
p-value = 0.2089) (Figure 14C). Relative mRNA levels of JAK1 from whole spinal cords of 
hSOD1G93A (9 weeks: n=6, 17 weeks: n=8) and non-transgenic (9 weeks: n=3, 17 weeks: 
n=5) were, also, similar (Figure 14D). 
 
 
 
4.2.6 Unchanged STAT1 levels in motor neurons from hSOD1G93A and 
non-transgenic adult mice 
Phosphorylated STAT1 is a measure of active JAK1/STAT1 signaling. Examining its 
expression could, thus, give an estimate of the degree of activation in the spinal motor 
neurons from hSOD1G93A and non-transgenic mice. Sections from cervical regions were 
stained for SMI32 and phosphorylated STAT1 for mice from both the genotypes. The CTCF 
values were unchanged as demonstrated by insignificant effects of age (F1,88 = 1.39, p-value = 
0.2438), genotype (F1,88 = 3.34, p-value = 0.0732), and genotype x age interaction (F1,88 = 
0.35, p-value = 0.5548) (Figure 15C). Measuring relative levels of STAT1 mRNA yielded 
similar expression in whole spinal cords of both presymptomatic and symptomatic 
hSOD1G93A mice (9 weeks: n=6, 17 weeks: n=8) and their age-matched controls (9 weeks: 
n=3, 17 weeks: n=5) (Figure 15). 
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Figure 14. Ex vivo Jak1 expression. Green channel shows Jak1 expression in cervical 
 
sections of both (A) presymptomatic and (B) symptomatic mice for both the genotypes. Scale 
 
bar = 10 μm. C) Jak1’s CTCF was similar in both nontg (n = 45 from 3 mice for each age 
 
group) and G93A mice (n = 45 from 3 mice for each age group) Two-way ANOVA with 
 
Bonferroni's correction (D) Jak1 mRNA is similar in spinal cords of G93A mice (9 weeks: 
n=6, 17 weeks: n=8) when compared to age matched nontg controls (9 weeks: n=3, 17 weeks: 
n=5) irrespective of the age group. Mann-Whitney test between every two groups. Data 
presented as scatter plots in one graph as mean ± SEM. 
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Figure 15. Ex vivo Stat1 expression. Green channel reflects Stat1 expression in cervical 
 
sections of both (A) presymptomatic and (B) symptomatic mice for nontg and G93A 
 
genotypes. Scale bar = 10 μm. C) Stat1 CTCF was similar in both nontg (n = 45 from 3 mice 
 
for each age group) and G93A mice (n = 45 from 3 mice for each age group) Two-way 
 
ANOVA with Bonferroni's correction (D) Stat1 mRNA is similar in whole spinal cords of 
 
G93A mice (9 weeks: n=6, 17 weeks: n=8) when compared to age matched nontg controls (9 
 
weeks: n=3, 17 weeks: n=5) in both symptomatic and presymptomatic groups. Mann-Whitney 
 
test between every two groups. Data presented as scatter plots in one graph as mean ± SEM. 
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4.2.7 Lowered expression of one of the catalytic subunits of Protein Kinase 
A in symptomatic hSOD1G93A mice 
JAK1/STAT1 signaling increases cellular cAMP that activates Protein Kinase A, which in 
turn phosphorylates GluR1 at position serine 845. With levels of JAK1 and activated STAT1 
similar between non-transgenic and hSOD1G93A motor neurons, the transcript expression of 
the catalytic subunits of PKA – PKAa and PKAb – were determined. In whole spinal cords 
from symptomatic hSOD1G93A mice, relative mRNA levels of PKAa were significantly 
lower as against those in age-matched control and presymptomatic mice. PKAb levels 
remained unchanged irrespective of the age group or genotype (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Protein Kinase A expression ex vivo. (A) PKAa mRNA is lower in whole 
spinal cords of hSOD1G93A symptomatic mice (17 weeks: n = 8) when compared to age-
matched nontg controls (9 weeks: n = 3, 17 weeks: n = 5) and presymptomatic 
hSOD1G93A mice (9 weeks: n = 6). However, (B) PKAb mRNA levels remained 
unchanged irrespective of symptom group in both nontg (9 weeks: n = 3, 17 weeks: n = 5) 
and hSOD1G93A (9 weeks: n = 6, 17 weeks: n = 8) mice. Mann-Whitney test between 
every two groups. Data presented as scatter plots in one graph as mean ± SEM. *p < 0.05. 
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5. DISCUSSION 
 
 
 
Calcium dysregulation and neuroinflammation have been well implicated in ALS as key 
 
pathogenic factors. This study shows that the ligand-binding subunit of the pro-inflammatory 
cytokine, IFN-©, called IFN-©R1 is upregulated in spinal motor neurons of adult 
hSOD1G93A mice in both presymptomatic and symptomatic stages of the disease. 
Moreover, GluR1, a subunit of AMPARs, that is involved in calcium dysregulation in 
ALS is enhanced in the motor neurons of symptomatic hSOD1G93A mice. These two 
receptor subunits, IFN-©R1 and GluR1, are primary participants of a non-canonical 
neuron-specific IFN-© pathway that is known to function via JAK1/STAT1 signaling upon 
IFN-© stimulation and inducing calcium influx (Mizuno et al., 2008). Upon examining the 
expression of the pathway’s downstream participants, this study shows similar levels of 
JAK1/STAT1 in motor neurons of both hSOD1G93A and non-transgenic mice ex vivo, 
unlike that of PKA wherein the transcript level of one of its catalytic subunits is lower in 
the spinal cords of symptomatic hSOD1G93A mice. Moreover, the ALS mutation carrying 
gene, hSOD1G93A, alone does not influence the expression of IFN-©R1 and GluR1, as seen 
in the expression studies of the subunits in vitro, which is representative of 
embryonic/early postnatal stage. Additionally, studying the functional effects of IFN-© in 
vitro reveals that the cytokine is weakly neurotoxic as it induces neuronal damage in spinal 
motor neurons observed as dendritic beads, but does not significantly alter cytosolic 
calcium levels or motor neuron survival in vitro. These functional effects would most likely 
be enhanced in the adult hSOD1G93A wherein higher levels of IFN-©R1 are present in 
the motor neurons. Thus, principally, this study presents IFN-©R1 as a potential target that 
could not only directly link neuroinflammation and neurodegeneration in ALS, but could also 
be modulated to regulate ALS progression. 
 
 
Despite several years of extensive research, ALS pathogenesis is still complex and not very 
 
well understood. Motor neuron death from excessive calcium influx due to over-stimulation 
 
of mostly AMPA receptors has been well documented, especially in the context of ALS. High 
 
calcium entry is often regarded as the maleficent force behind AMPAR mediated excitotoxic 
 
motor neuron death in ALS (Grosskreutz et al., 2010; Patai et al., 2016). Ironically, despite 
 
being susceptible to excitotoxicity, motor neurons did not evolve to house sufficient levels of 
 
calcium-binding proteins and exhibit lower density of mitochondria per cell volume to buffer 
 
the cytosolic calcium (Grosskreutz et al., 2007; Tadic et al., 2014). This paradox can be 
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explained by the physiological need of the motor neurons to activate rapidly and efficiently 
 
via calcium cycling for muscle contraction and expansion. Presence of good calcium 
 
buffering system would mean lack of readily available free calcium for signaling and other 
 
associated molecular processes. 
 
 
 
Neurodegeneration in ALS is mostly from activation of inflammatory pathways involving 
 
stimulated microglia and infiltrating lymphocytes. There are several studies on cellular 
 
players and molecular mechanisms of neuroinflammation in ALS (Liu & Wang, 2017). 
 
However, there is no record till date that focuses on a pathway that could directly link motor 
 
neuron degeneration and neuroinflammation along the axis of calcium dysregulation, a key 
 
common denominator in ALS pathogenesis (Patai et al., 2016). In one previous study, cortical 
neuron dysfunction via calcium influx was demonstrated upon IFN-© stimulation in vitro 
in healthy mice. Following up on this study, the present work focuses on studying the 
involved pathway in spinal motor neurons in both the hSOD1G93A ALS mouse model 
and healthy non-transgenic mice. Including the latter kind not only helped serve the purpose 
of having a natural non-transgenic control, but also gain insights in healthy cases. Moreover, 
the pathway was examined in motor neurons both in vitro, which represents the embryonic 
stage, as well as ex vivo in adult mice. 
 
 
 
5.1 Dendritic beads in hSOD1G93A and non-transgenic motor-neuron 
co-cultures 
Neuritic beading is an early hallmark of neuronal toxicity that has been reported in several 
pathological conditions like Alzheimer’s disease, Amyotrophic Lateral Sclerosis, CNS 
trauma, and other related conditions (Delisle & Carpenter, 1984; Hori & Carpenter, 1994; 
Takahashi et al., 1997; Dickson et al., 1999; Mattila et al., 2000; Swann et al., 2000; Goel et 
al., 2003; Saito et al., 2003). Cellular events that trigger the focal bead-like swelling include 
stimuli from glutamate, oxidative stress, hypoxia, and hypotonic conditions. The functional 
role of these beads in pathological conditions is still unclear. Excitotoxic stimulus triggers 
influx of water along with sodium and chloride ions in neurons to induce bead formation by 
mechanisms that are unknown till date. Subsequent calcium entry maintains the 
morphological changes in the damaged dendrites (Hasbani et al., 1998). Interestingly, IFN-γ 
has, also, been shown to induce dendritic beads in vitro in primary mouse cortical neuron 
cultures (Mizuno et al., 2008). 
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In this study, to determine if this neurotoxic effect of IFN-© is recapitulated in spinal motor 
 
neurons, primary motor neuron-astrocyte co-cultures from both hSOD1G93A and non- 
 
transgenic mice were incubated with IFN-γ for 12 hr. Dendritic beads were observed in both 
 
the genotypes when compared to neurons from untreated co-cultures. This could be due to the 
functioning of the IFN-©R1:GluR1 pathway as demonstrated in the previous cortical 
neuron study (Mizuno et al., 2008). Another explanation could be low numbers of microglia 
that get activated by IFN-γ and induce neuritic beading (Takeuchi et al., 2005). 
However, if it is glial-cell mediated, the beading process most likely would take 
more than 12 hours considering the involvement of an intermediate participant. 
Nevertheless, this observation indicates the neurotoxic effect of IFN-γ, irrespective of the 
presence of hSOD1G93A gene. 
 
 
 
5.2 AMPAR-mediated excitotoxicity unaffected by IFN-γ 
 
Dendritic beading implies that IFN-γ works on the primary motor neuron co-cultures and 
 
induces damage. To further explore its neurotoxic role, the cell cultures from both genotypes 
 
were treated with IFN-γ and kainate (a potent AMPAR agonist) in combination or alone for 
 
12 & 24 hr. 
 
 
 
Sole application of IFN-γ to our primary motor neuron-enriched co-cultures did not kill the 
 
motor neurons. This observation that IFN-γ is independently not lethal to the motor neurons 
 
supports similar previous studies of the cytokine on neurons (Mizuno et al., 2008; O’Donnell 
et al., 2015). Interestingly, in a different study, hSOD1G93A astrocytes releasing IFN-γ was 
shown to induce neuronal death to similar degrees in both wild-type hSOD1 and 
hSOD1G93A motor neurons in a LIGHT-dependent manner (Aebischer et al., 2010). 
However, it would be important to note that this apparent lethal effect was observed only at 
disease onset and symptomatic stage of the ALS mouse model implying significant 
neurotoxic effects of IFN-γ via astrocytes mostly during ALS progression. 
 
 
Additional observation in our cell survival study was the AMPAR-mediated excitotoxicity 
 
that was unaffected by IFN-γ. This was interesting as it contrasted with similar study on 
 
cortical neurons (Mizuno et al., 2008). There are a few possibilities that can explain this 
 
detection apart from the fact that a different AMPAR agonist was used in the previous study 
 
as against the current one. 
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Firstly, motor neurons have a high concentration of AMPARs and are highly vulnerable to 
 
kainate. This agonist incessantly binds to AMPARs and mediates excitotoxic death via fast 
kinetic reaction. On the other hand, IFN-γ induced neurotoxicity via IFN-©R1:GluR1 
receptor complex formation requires activation of a pathway involving a cascade of steps that 
could be more time-consuming (Figure 17). Secondly, IFN-γ is not lethal to motor neurons in 
vitro and induces only weak neurotoxicity that demonstrated as dendritic beads. Taken 
together, this suggests that combining both kainate and IFN-γ could result in a neurotoxic 
response wherein the weak effect of IFN-γ is most likely masked by the strong excitotoxic 
kainate response. This is corroborated in the 24 hr study wherein percentage of surviving 
motor neurons further decreases to extremely low numbers with kainate as against hardly 
any changes in motor neuron survival that underwent IFN-γ treatment alone. Thirdly, 
Major Histocompatibility Complex-1 (MHC-1) on motor neurons can, also, influence its 
susceptibility to neurotoxicity. This happens in two ways: IFN-γ upregulates MHC-1 in 
motorneuron-astrocyte co-cultures (Nardo et al., 2016) that can lead to enhanced AMPAR 
trafficking (Fourgeaud et al., 2010), thus, culminating in higher calcium influx upon 
AMPARs stimulation alone. On the other hand, hSOD1G93A astrocytes can lower MHC-1 
expression in motor neurons and make them more vulnerable to neurotoxicity (Song et al., 
2016). Among the two aforementioned ways, the former could most likely be a reason 
behind our cell survival study’s observation as the latter was demonstrated only in 
symptomatic hSOD1G93A mice. Finally, IFN-γ is known to activate protective non-
canonical signaling in primary neurons via Erk1/2 involving pathway (O’Donnell et al., 
2015) and this could be considered as a standalone explanation behind unaffected 
AMPAR-mediated excitotoxicity. However, bringing the observation of dendritic beads into 
the picture, it can be stated that the protective non-canonical signaling is most likely not 
activated in the motor neurons from our cell survival study. 
 
 
As for the apparent contrasting observations of the survival study with the dendritic beading 
 
observation, it would be critical to note that formation of the beads is a much more rapid 
 
process as compared to calcium-mediated excitotoxic injury (Hasbani et al., 1998). Hence, it 
 
could be that the IFN-γ induces neurotoxicity, but enhancing AMPAR mediated excitotoxicity 
 
might be a slower and weaker process in hSOD1G93A motor neurons. 
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Figure 17. Hypothetical model explaining kainate-mediated excitotoxicity unaffected by 
IFN-γ. (A) IFN-γ binds to IFN-©R1 leading to downstream activation of JAK1 
and recruitment of STAT1 following phosphorylation. Phosphorylated STAT1 activates 
adenylyl cyclase, which in turn increases cAMP levels resulting in activation of PKA and 
subsequent phosphorylation of GluR1 subunit of AMPAR. This induces formation of a 
neuron-specific calcium permeable receptor complex between AMPAR and IFN-©R1. (B) 
When both kainate and IFN-γ are present, fast-kinetic reaction occurs wherein kainate 
incessantly opens the AMPAR to allow calcium entry. In contrast, IFN-γ follows 
sequential steps to mediate formation of calcium-permeable complex with already active 
AMPARs. 
 
 
 
5.3 Weak single cell calcium responses from neurons of hSOD1G93A and 
non-transgenic motor-neuron co-cultures upon direct IFN-γ treatment 
Upon IFN-γ stimulation, neuronal damage due to excessive calcium influx in cortical neurons 
has been observed in previous study (Mizuno et al., 2008). Moreover, AMPAR stimulation by 
potent agonists like kainate triggers neuronal death by inducing intracellular calcium influx, 
which is enhanced in hSOD1G93A motor neurons (Grosskreutz et al., 2010). Apart from 
studying the effect of IFN-γ on neuronal survival, this study examined the effect of the 
cytokine on cytosolic calcium levels. 
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For our motor neuron co-culture system, several protocols were tested to elicit a strong 
 
calcium signal in the single cell measurements: low doses (100 ng/ml, 200 ng/ml) and high 
 
dose (500 ng/mLIFN-γ) direct short and long-term application both in the presence and 
 
absence of other channel blockers; pre-incubation with IFN-γ followed by kainate stimulation 
 
in the presence and absence of other channel blockers. In all the tested experimental 
 
conditions, the cytosolic calcium responses were weak and inconsistent, thus, implying that 
 
IFN-γ is most likely directly triggering calcium influx, but is not potent enough to elicit a 
 
large signal. The weak responses can be due to the possible presence of this receptor complex 
 
majorly in the extrasynaptic region as compared to the synapses as suggested in a previous 
 
study (Mizuno et al., 2008). This can be confirmed in future studies with electrophysiological 
 
recordings, a theme that is beyond the scope of this study. Moreover, the occasional 
 
spontaneous calcium transients observed as asynchronous signals in the absence of the 
channel blockers (Table 17.C) demonstrate that the signals were from live neurons that were 
unperturbed by mechanical application of the cytokine (Grosskreutz et al., 2007). To compare 
the strength of the calcium signals from IFN-γ and confirm that the cultures were alive, 
independent measurements after sole kainate application were, also, done in parallel (Figure 
18). 
 
Figure 18. Representative cytosolic calcium 
measurements from kainate stimulation. AMPARs of 
spinal motor neurons were stimulated with 100 µM kainate 
for 2 seconds at every 100 second interval in the presence of 
verapamil and TTX. 
 
 
 
 
5.4 IFN-γR1 expression in hSOD1G93A motor neurons 
 
Apart from intracellular calcium, IFN-γ also regulates several immune responses. In 
 
hSOD1G93A mice, cytokine profiling showed high levels of IFN-γ throughout the ALS 
 
disease course starting from onset (Michaelson et al., 2017). However, expression of its 
 
receptor’s ligand binding unit, IFN-γR1, has not been investigated till date in ALS. Classical 
 
IFN-γ pathway involves participation of ligand binding IFN-γR1and signal transducing IFN- 
 
γR2 subunits of the IFN-γ receptor. For this piece of work, IFN-γR1 is our target of interest. 
 
We examined the distribution and expression of the receptor subunit initially in primary motor 
 
neurons that represent embryonic stage in both hSOD1G93A and non-transgenic motor 
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neuron-astrocyte co-culture systems. Both relative mRNA and protein levels were measured 
 
by qPCR and immunofluorescence methods respectively. 
 
 
 
Our experiments revealed similar levels of IFN-γR1 expression at both mRNA and protein 
 
levels, irrespective of the genotypes in vitro. It is known that IFN-γR1 is constitutively 
 
expressed on all cell types at moderate level (Bach et al., 1997). Thus, our observation in 
 
mice primary motor neurons suggests that hSOD1G93A presence does not alter expression or 
 
distribution of the receptor subunit atleast in the embryonic stage. The receptor subunit was 
 
uniformly distributed across the cell somas, apart from a concentrated signal in the nucleus. 
 
This could most likely be from certain fraction of IFN-γR1 that translocated to the nucleus to 
 
regulate gene expression (Ahmed & Johnson, 2006). 
 
 
 
Considering that the immune cells of the CNS acquire inflammatory phenotype with age 
 
and/or disease progression(Fenn et al., 2015), expression of IFN-γR1 was, also, examined in 
 
the motor neurons of adult hSOD1G93A mice. Since the pattern of disease spread in this 
 
mouse model is from lumbar to cervical region (Beers et al., 2011), the spinal cord sections 
 
for IFN-γR1 protein study were taken from the cervical regions of hSOD1G93A mice and 
 
their age-matched controls. For relative mRNA measurements, whole spinal cords were 
 
employed. Considering that IFN-γ levels are higher in motor neurons from spinal cords of 
 
diseased hSOD1G93A mice, IFN-γR1 also should be ideally upregulated. True to the 
 
hypothesis, IFN-γR1 protein levels were higher in motor neurons of symptomatic 
 
hSOD1G93A mice as against their age-matched controls. Surprisingly, the receptor unit was 
 
upregulated in motor neurons of presymptomatic hSOD1G93A mice, too. It is to be noted 
 
here that IFN-γR1 expression can be enhanced by proinflammatory cytokines like TNF-α and 
 
IL-1β, which are elevated at early stages in hSOD1G93A mice (Michaelson et al., 2017). 
 
Additionally, post-translational modifications could potentially be elevated in hSOD1G93A 
 
mice that lead to receptor stability (Londino et al., 2017). These studies, also, explain the 
 
reason for lack of enhanced IFN-γR1 expression in embryonic hSOD1G93A motor neurons. 
 
 
 
 
 
In contrast to the protein expression studies, relative mRNA measurements from whole spinal 
 
cords reveal no change in expression. Apart from reasons stated for elevated IFN- 
 
γR1expression in motor neurons, an additional explanation for the mRNA results could be the 
 
fact that the IFN-γR1 signal in the qPCR comes from a plethora of cells with motor neurons 
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constituting only a fraction of the cell population. mRNA measurements exclusively from 
 
cervical regions were not attempted owing to very low amounts of generated cDNA sample. 
 
Collectively, the IFN-γR1expression results suggest that mere hSOD1G93A gene presence 
 
does not influence the receptor subunit’s expression and that this is most likely regulated by 
 
several physiological factors in the adult mice. 
 
 
 
Presence of high levels of IFN-γR1 imply priming of hSOD1G93A motor neurons to immune 
 
responses and being susceptible to IFN-γ associated signaling even before disease onset. To 
 
our knowledge, this is the first study on IFN-γR1 expression in spinal motor neurons of any 
 
ALS mouse model. 
 
 
 
5.5 GluR1 expression in motor neurons of hSOD1G93A mice 
 
GluR1 is one of the key AMPAR subunits that is present in spinal motor neurons and 
 
contributes to their excitotoxic death. For our study, similar to IFN-γR1expression analysis, 
 
we initiated examining the expression of GluR1 with primary motor neuron co-cultures that 
 
are representative of embryonic/early postnatal period. Both mRNA and protein expression 
 
analyses revealed unchanged GluR1 expression despite the presence of hSOD1G93A gene. 
This supports the fact that GluR1 is developmentally regulated in spinal motor neurons 
(Jakowec, Yen, et al., 1995). 
 
 
Expression study in motor neurons from adult spinal cords revealed barely detectable levels of 
 
GluR1 in presymptomatic hSOD1G93A mice and their age-matched control. This observation 
 
is in sync with a previous study that showed that levels of GluR1 decrease with age in healthy 
 
rat spinal cord in a fashion such that by adulthood, the motor neurons express very low to no 
 
levels of the subunit transcript (Jakowec, Fox, et al., 1995). 
 
 
 
However, in the symptomatic hSOD1G93A motor neurons, elevated levels of GluR1 were 
 
observed as against barely detectable levels in the motor neurons from age-matched control. 
 
In an earlier study, total GluR1 levels in spinal motor neurons of presymptomatic 
 
hSOD1G93A mice were observed to be higher at 17 weeks of age when compared to those 
 
from hSOD1 wildtype controls (Zhao et al., 2008). But, this was not observed in 
 
hSOD1G93A mice that were younger than 17 weeks. This implies that with age, GluR1 levels 
 
most likely increase in motor neurons of hSOD1G93A mice, thus, supporting our study. 
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Moreover, high levels of MHC-1 in symptomatic mice can positively regulate expression of 
 
GluR1 on membrane surface (Fourgeaud et al., 2010). Another explanation behind elevated 
 
GluR1 in motor neurons of symptomatic hSOD1G93A mice is the subunit’s upregulation by 
 
cytokines like TNF-α that are increased in the spinal cords of ALS mice (Stellwagen et al., 
 
2005). Elevated GluR1 levels, also, suggest changes in dendritic complexity and in the 
 
diseased case, this might contribute to abnormal motor movements (Inglis et al., 2002; 
 
Prithviraj et al., 2007), a feature observed in ALS. 
 
 
 
5.6 Unchanged JAK1 levels in adult hSOD1G93A mice motor neurons ex 
vivo 
Primary targets of the neuron-specific IFN-γ pathway were overexpressed in adult 
hSOD1G93A mice motor neurons, especially in the symptomatic stage. To determine if the 
pathway is overall upregulated, measuring expression of key downstream targets is, also, 
essential. The first downstream target involved in this non-canonical signaling is JAK1. 
Measuring relative mRNA and protein levels demonstrated similar JAK1 levels between 
hSOD1G93A and non-transgenic mice irrespective of the disease stage. Studies on 
differential expression of inflammation related genes in hSOD1G93A mice revealed JAK3 as 
the only member from the Janus Kinase family that was upregulated in both presymptomatic 
and symptomatic ALS mice (Yoshihara et al., 2001). This implies that JAK1 expression is 
unchanged throughout the disease course, which supports our observation. Moreover, cellular 
JAK1 is associated with other proteins, also, apart from IFN-γR1. Thus, increased IFN-γR1 
need not necessarily correlate with high levels of JAK1. The expression of this downstream 
target was not examined in primary motor neuron culture considering similar expression 
levels of the primary targets, IFN-γR1 & GluR1. 
 
 
 
 
 
5.7 Similar levels of activated STAT1 in adult hSOD1G93A and non-
transgenic mice motor neurons ex vivo 
Regarding the STAT members, while some STATs like STAT2, STAT4, and STAT6 have 
specific activation patterns, others like STAT1 and STAT3 can be activated by several 
cytokines (Pestka et al., 1997). Phosphorylated STAT1 (pSTAT1) is the activated form of 
STAT1, whose expression was examined in motor neurons ex vivo in the present study. 
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pSTAT1 is known to be upregulated in astrocytes of presymptomatic hSOD1G93A mice. 
 
Interestingly, unlike astrocytes, motor neurons from hSOD1G93A mice in our study showed 
 
similar pSTAT1 levels when compared to age-matched controls, irrespective of the disease 
 
stage. This was, also, supported by mRNA results. Similar STAT1 levels along with 
 
unchanged JAK1 levels indicate that although the surrounding milieu of the motor neurons 
 
have upregulated JAK1/STAT1 signaling induced by IFN-γ in hSOD1G93A, the signaling is 
 
most likely not enhanced in the neurons themselves. This could be an attempt to counter 
 
balance inflammatory reactions, notwithstanding the presence of higher levels of IFN-γR1. 
 
 
 
These results, also, throw light on the complexity of receptor signaling in neurodegenerative 
 
conditions like ALS wherein some of the players are upregulated while many others are not. 
 
As was for JAK1, the expression study of STAT1 also was not attempted in motor neuron co-
cultures. 
 
 
 
5.8 Decreased expression of one of the two catalytic subunits of PKA in 
 
symptomatic hSOD1G93A mice ex vivo 
 
Protein Kinase A (PKA) is the best described kinase member of the protein kinase 
 
superfamily that is principally involved in modifying proteins by phosphorylating them. Its 
 
activity is dependent on intracellular cAMP whose levels are regulated by the enzyme 
 
adenylyl cyclase. Functional mouse PKA has 2 catalytic isoforms in action: PKAa and PKAb. 
 
As a form of preliminary investigation, the transcript levels of these catalytic isoforms were 
 
analyzed in this study. Although relative mRNA levels of PKAb in hSOD1G93A mice were 
 
similar to non-transgenic age-matched controls, lower PKAa mRNA levels were observed in 
 
symptomatic hSOD1G93A mice. This implies that there could be a downregulation in PKA 
 
activity post disease onset. Expression study of protein kinases and phosphatases in spinal 
 
cords of hSOD1G93A mice revealed unchanged PKA expression (Hu et al., 2003) as against 
 
wild-type hSOD1 controls. The digression in our expression study could be due to use of non- 
 
transgenic animals as against wild-type hSOD1 as the control system. Additionally, decreased 
 
PKA signaling has been observed in neurodegenerative disorders (Dagda & Das Banerjee, 
 
2015) that supports our preliminary observation of PKA levels. Combining our results on 
 
downstream targets with previous studies presents the complexity of this non-canonical IFN-γ 
 
signaling in adult hSOD1G93A mice and the need for a full-fledged independent study to 
 
examine the cascading events in further detail in adult mice. 
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5.9 Strengths and limitations of the study 
 
The study’s experimental framework utilized both the well-established motor neuron-enriched 
 
primary cell culture system as well as adult spinal cord cervical sections from hSOD1G93A 
 
mice and the non-transgenic controls. While the former system is representative of embryonic 
 
stage, the ex vivo studies gave insights into the pathway in motor neurons from adult mice 
 
spinal cords. The primary motor neuron co-culture system presents several advantages for 
 
investigating neurodegeneration in ALS. First, the primary cell cultures reflect disease 
 
features more accurately than immortalized cell lines. Second, co-cultivation with astrocyte 
 
glia bears semblance to the actual physiological state of the neurons in the spinal cord wherein 
 
the neurons are in a glial cell environment. Most importantly, the parallel cultivation of 
 
transgenic (ALS) and non-transgenic (control) cells can define disease-specific molecular 
 
characteristics. However, primary cell culture preparation doesn’t lend itself to sample- 
 
intensive techniques like Western Blotting. Moreover, the inability to physically extract 
 
mature motor neurons from glial feeder layers also renders mixed signals in qPCR. The 
 
observation of dendritic beads could have been supported by a co-localization study of the 
 
receptor complex, but considering the available resources including time and the fact that the 
 
cytokine exerted minimal functional changes, this additional experiment would add more 
 
value if done in future studies involving ex vivo specimens rather than in vitro. It is, also, 
 
critical to note that although disease-associated proteins or pathways are examined in the 
 
hSOD1G93A mouse system, such animal models never fully recapitulate the disease as it is 
 
observed in humans. For instance, the transgene gross overexpression used to generate the 
 
hSOD1G93A model results in toxic offshoots that significantly accelerate the disease course 
 
to the degree that measuring a clinically relevant outcome becomes very difficult (Zwiegers & 
 
Shaw, 2015). 
 
 
 
The ex vivo studies might bear more similarity to the disease pathology in patients than in 
 
vitro cell culture studies. Whole spinal cords from adult mice were employed for the 
 
expression studies. Motor neurons were imaged from spinal cord sections and protein 
 
expression was analyzed using standard expression analysis methods like ImageJ. mRNA 
expression analyses for the targets of interest were, also, carried out. This resulted in a clearer 
picture of the expression of the key upstream and downstream participants of the non-
canonical neuron-specific IFN-γ pathway in the disease model, unlike in the case of pure gene 
expression approach in vitro wherein the gene expression itself may or may not reflect the 
actual protein expression. 
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Motor neurons were identified by SMI32 staining and the targets of interest found only in 
 
these neurons were evaluated. Western blots employing whole spinal cords implied that the 
 
target mRNA values would be from the all the different cell types and, hence, were not 
 
carried out. Due to the lack of a cell isolation arrangement that would help isolate pure motor 
 
neurons from the anterior horn spinal cord grey matter, immunofluorescence based approach 
 
was used for protein expression. The imaging for ex vivo protein expression has not been 
 
performed on a perfect three-dimensional cut-out of target cells owing to absence of an ultra- 
 
high resolution imaging system and software that could demarcate cells along their respective 
 
membranes either manually or automatically. The analyzed z-stacks contain irregularly 
 
shaped neuronal cell bodies that may or may not be perfectly perpendicular to the border 
 
planes of the scan. This implies that although the majority of the signal data are from the cell 
 
observed, a certain amount of “fluorescence bleed-through” from both underneath and above 
could be present from neighboring cell populations, thus, giving us bit of a flawed picture of 
protein expression. Considering this, a great deal of attention was paid to fix the border planes 
of the z-stacks as close as possible to the investigated motor neurons to drastically reduce the 
noise. In the case of mRNA analyses, whole spinal cords were used instead of cervical regions 
alone. This was owing to technical difficulties involved with precise extraction of such a 
small specimen and very low resulting mRNA yield. The whole spinal cords contained 
various cell subpopulations like sensory neurons, microglia, astrocytes, and other cell types. 
This could, in fact, lead to lack of result supporting protein expression studies by potentially 
obscuring significant findings in motor neurons. 
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6. CONCLUSIONS AND OUTLOOK 
 
 
To summarize the findings of this study, IFN-γR1 is upregulated on motor neurons from both 
 
presymptomatic and symptomatic hSOD1G93A mice. This strongly offers the possibility of 
 
increased sensitivity of the motor neurons to IFN-γ signaling, both canonical and non- 
 
canonical. Higher levels of AMPAR subunit GluR1 in motor neurons of symptomatic 
 
hSOD1G93A mice imply that the neuron-specific non-canonical IFN-γ pathway could be 
 
upregulated in disease stage in the event that the downstream targets – JAK1, STAT1, PKA – 
 
are, also, functionally upregulated. Interestingly, the expression results failed to be 
 
recapitulated in embryonic motor neurons of hSOD1G93A mice, thus, suggesting that 
 
presence of ALS mutation alone is not enough to influence the expression. Presence of 
 
dendritic beads in primary motor neurons implies neuronal damage inducing function of IFN-
γ. Lack of enhanced AMPAR-mediated excitotoxicity and significant calcium signals upon 
IFN-γ treatment are most likely due to absence of enough strength in neurotoxicity by IFN-γ. 
 
 
This study opens doors to several areas that can be explored in the future. In this piece of 
 
work, only expression studies of targets of interest were carried out in adult mice. The 
 
pathway and its functional aspects can be investigated in detail by performing experiments in 
 
adult hSOD1G93A mice. Moreover, this study can be extended to ALS patients by employing 
 
tissues collected from post-mortem cases. These studies would not only yield further insights 
 
on the interplay between neurodegeneration and neuroinflammation in ALS, but pave way to 
 
finding more therapeutic strategies as well. 
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